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iNtRoDuCtioN
by Eve Marder, Ph.D.
President, Society for Neuroscience
I bring here perspectives of an unabashed and unapologetic basic scientist looking at a Progress Report that summarizes recent 
findings of fundamental importance to us and 
our families as we live our present lives and face 
our futures.
As a scientist, I have been privileged to work 
on the most basic of neuroscience problems, 
such as homeostatic regulation (maintaining stable neuronal function 
over a lifetime), only to discover that scientists interested in clinical 
problems such as epilepsy find it relevant to their work.1, 2 At the 
same time, as a daughter, I watched with amazement as my father 
recovered from traumatic brain injury suffered as a consequence of a 
traffic accident. To this day I marvel at the extent to which his then 
76-year-old brain rebuilt itself so that, almost seven years later, no one 
meeting him for the first time would dream that anything untoward 
had happened.
That said, his recovery is more a testament to the extraordinary 
ability of the human brain to recover from insult, and to the skill of a 
surgeon, than it is to our understanding of how and why his recovery 
was so complete. There is nothing more disconcerting to a neurosci-
entist than watching a close friend or family member dealing with a 
brain injury or disease, knowing how little we presently understand, 
and I welcome all of the advances described in this volume.
As a research scientist working in a liberal arts university, I teach 
a course titled “Principles of Neuroscience” in which I cover the full 
range of basic neuroscience and its application to issues of direct 
clinical and human problems. As an educator, I find extremely 
satisfying the astonishing numbers of instances in which arcane 
details addressed by scientists following the most basic of research 
topics set the stage for understanding clinical conditions. Likewise, 
in this collection of essays, I find equally satisfying the numerous 
instances in which work done over many years by basic scientists 
2has led to important advances that will eventually result in enhanced 
human outcomes.
One of the great mysteries of our lives is why and how individu-
als, growing up in families of all kinds, become painters, musicians, 
or dancers. We all have noticed the degree to which aptitude and 
practice of the arts “runs in families.” Is that due to genetics, to early 
exposure and training, or to both? There are urban legends that 
mathematicians and physicists make good musicians. Is there really a 
connection with the cortical states that allow individuals to do formal 
abstract thinking and music? Will educating our children in the arts 
enhance other kinds of cognitive development? These are the kinds 
of questions that the Dana Arts and Cognition Consortium has begun 
to address.
Disorders that affect children, such as autism, attention-deficit/
hyperactivity disorder, and mental retardation, are among the most 
heartbreaking of all neurological problems. Also devastating are 
neurodegenerative diseases, such as Huntington’s disease, Parkinson’s 
disease, and Alzheimer’s disease, that affect adults. Recent work shows 
the power of genetics in understanding the causes of some of these 
disorders. Indeed, we are seeing today the fruit of decades of work on 
fundamental genetic mechanisms, as we now have the tools to study 
the role of interactions of multiple genes in complex human disease. 
The same message emerges from recent work on brain tumors: Much 
hope for developing new treatments for gliomas and other brain 
tumors is coming from studies of the cellular signaling pathways that 
are controlling the growth and proliferation of cancers of all kinds, 
including those of the brain.
It was rapid surgical intervention that saved my father’s brain, 
and recent progress on stroke, highlighted in this volume, shows 
that timely intervention is also crucial for the protection of the brain 
in response to stroke and transient ischemic attacks that produce 
seemingly minor neurological effects. Timely interventions following 
a transient ischemic attack are now shown to decrease the risk of 
an additional, more serious, stroke in the weeks following the first 
evidence of ischemic neurological events.
In many human disorders it can be particularly difficult to 
translate the intuitions and findings from animal models into clinical 
practice. Excellent and well-controlled clinical trials are critical for 
this enterprise, but it can often be difficult to ensure that clinical trials 
are done correctly. Toward this end, the International Campaign for 
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Cures of Spinal Cord Paralysis has worked to develop new criteria 
for patient participation and assessment in clinical trials of potential 
treatments for spinal cord injury. Equally important are the criteria 
for clinical trials in all arenas in which evaluation of treatments for 
any neurological or psychiatric disorder is needed.
The past year has seen a remarkable explosion of interest in a series 
of issues, grouped together in the young field of neuroethics, to which 
the American Journal of Bioethics now devotes three issues a year. Four 
topics garnered significant attention in 2007: commercialization of lie 
detection, deep brain stimulation for the treatment of depression, 
genetic studies of addiction, and brain imaging. Here we are seeing 
unanticipated and thorny consequences of the development of new 
technologies for the diagnosis and treatment of brain disorders. This 
comes at the same time as remarkable advances in stem cell biology, 
which may free us from many of the controversies around the use of 
stem cells from human embryos.
Meanwhile, interactions between the immune system and the 
nervous system are becoming more tangible. In no case is this more 
evident than with multiple sclerosis, a disorder in which genetic and 
environmental factors influence the immune system’s attack on the 
myelin sheath surrounding many nerve cells. Recent studies have 
demonstrated a link between several immune-system genes and risk 
for multiple sclerosis. Fascinating recent findings suggest an important 
link between vitamin D, sun exposure (which increases vitamin D), 
the immune system, and multiple sclerosis. The immune system may 
also be important in understanding some chronic pain syndromes.
The mechanisms that produce chronic pain syndromes are myste-
rious, and they may include maladaptive responses to injury that 
outlast the initial insult. Because significant chronic pain is so 
debilitating and often difficult to treat effectively, new insights into 
the organization and function of pain pathways are required, and new 
kinds of treatments particularly welcome. This is especially the case 
as researchers try to provide alternatives to long-term use of opioid 
drugs, with their potential for becoming addictive. Among the most 
promising new treatments now under study are neurostimulation, 
with electrodes implanted either near the spinal cord or peripher-
ally. These methods are intended to use direct stimulation to block 
the pain signals before they reach the brain. Elsewhere, fascinating 
new studies provide insight into how the brain produces fever in 
response to infection,3 again drawing on our new understanding of 
4basic cellular signaling mechanisms and our ability to genetically 
manipulate these in animal models.
Sadly, the major psychiatric disorders, such as schizophrenia, 
depression, and addiction, first manifest in many individuals when 
they are adolescents and young adults, at a time when they should 
be ready and able to enter and contribute to society creatively and 
independently. Research in 2007 is contributing to a paradigm shift in 
the understanding of these disorders.
For a long time scientists had focused on the search for single 
biochemical and molecular causes. Now we understand that thought 
and mood disorders could be a consequence of faulty connectivity 
in brain circuits, even if each neuron is functioning correctly. New 
imaging techniques and genetic manipulations are enhancing the 
search for genes that play a role in the establishment and maintenance 
of appropriate circuit structure under a variety of environmental 
conditions. Moreover, this change in paradigm should support 
investigation into a variety of new ways of treating these disorders. 
It will also help us understand the kinds of cognitive disorders that 
result from loss of specific components of circuits as neurons die in 
neurodegenerative diseases, such as Alzheimer’s disease.
One of the biggest difficulties in treating psychiatric disorders is 
the extreme heterogeneity of the population, and one of the biggest 
hopes for the future is that the choice of drug or other treatment 
will be made with knowledge of the likelihood that the treatment 
will be effective for that individual, on the basis of his or her 
genetic makeup.
Many young scientists are drawn to the field of neuroscience 
by fascination with its really “big” questions, such as the nature of 
consciousness, the structure of human thought, and the relationship 
between specific brain structures and our ability to use language, 
appreciate music, and relate to others. Work in 2007 brings us closer 
to understanding how the brain, composed of circuits of neurons, 
actually functions during complex cognitive acts.
Despite the extraordinary insights into brain function in health and 
disease, each new finding only makes it clearer how much remains to 
be understood. For example, we all experience mental fatigue, but 
we haven’t a clue what the biological correlates of mental fatigue are. 
We all know that each person’s brain is different, that each of us has 
stored different memories and uses those to respond uniquely to each 
other and to the world. At the same time, we believe that the essential 
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rules by which our brains operate are conserved, most of them not 
only in the human population but across the animal kingdom. How 
we understand our individual human attributes in the context of our 
shared sets of biochemical, molecular, and genetic mechanisms is the 
major challenge for future work.
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ARtS AND CoGNitioN:
fiNDiNGS hiNt At RElAtioNShiPS
by Michael S. Gazzaniga, Ph.D.
In 2004, the Dana Arts and Cognition Consortium brought together cognitive neu-roscientists from seven universities across 
the United States to grapple with the question 
of why arts training has been associated with 
higher academic performance. Is it simply that 
smart people are drawn to “do” art—to study 
and perform music, dance, drama—or does early 
arts training cause changes in the brain that enhance other important 
aspects of cognition?
The consortium can now report findings that allow for a deeper 
understanding of how to define and evaluate the possible causal 
relationships between arts training and the ability of the brain to learn 
in other cognitive domains.
The research includes new data about the effects of arts training 
that should stimulate future investigation. The preliminary conclu-
sions we have reached may soon lead to trustworthy assumptions 
about the impact of arts study on the brain; this should be helpful 
to parents, students, educators, neuroscientists, and policymakers in 
making personal, institutional, and policy decisions.
Specifics of each participating scientist’s research program are 
detailed in the appended reports, which can be downloaded from 
www.dana.org. Here is a summary of what the group has learned:
An interest in a performing art leads to a high state of 1. 
motivation that produces the sustained attention necessary to 
improve performance and the training of attention that leads 
to improvement in other domains of cognition.
Genetic studies have begun to yield candidate genes that may 2. 
help explain individual differences in interest in the arts.
Specific links exist between high levels of music training and 3. 
the ability to manipulate information in both working and 
8long-term memory; these links extend beyond the domain of 
music training.
In children, there appear to be specific links between the prac-4. 
tice of music and skills in geometrical representation, though 
not in other forms of numerical representation.
Correlations exist between music training and both reading 5. 
acquisition and sequence learning. One of the central predic-
tors of early literacy, phonological awareness, is correlated 
with both music training and the development of a specific 
brain pathway.
Training in acting appears to lead to memory improve-6. 
ment through the learning of general skills for manipulating 
semantic information.
Adult self-reported interest in aesthetics is related to a 7. 
temperamental factor of openness, which in turn is influenced 
by dopamine-related genes.
Learning to dance by effective observation is closely related to 8. 
learning by physical practice, both in the level of achievement 
and in the neural substrates that support the organization of 
complex actions. Effective observational learning may transfer 
to other cognitive skills.
The foregoing advances our knowledge about the relationship 
between arts and cognition. These advances constitute a first round 
of a neuroscientific attack on the question of whether arts training 
changes the brain to enhance general cognitive capacities. The ques-
tion is of such wide interest that, as with some organic diseases, insup-
portable answers gain fast traction and then ultimately boomerang.
This is the particular difficulty of correlations; the weakness and 
even spuriousness of some correlational studies led to the creation of 
the consortium. Correlation accompanies, parallels, complements, or 
reciprocates, and is interesting to observe, but only an understanding 
of mechanisms drives action and change.
Although scientists must constantly warn of the need to distinguish 
between correlation and causation, it is important to realize that 
neuroscience often begins with correlations—usually, the discovery 
that a certain kind of brain activity works in concert with a certain kind 
of behavior. But in deciding what research will be most productive, 
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it matters whether these correlations are loose or tight. Many of the 
studies cited here tighten up correlations that have been noted before, 
thereby laying the groundwork for unearthing true causal explana-
tions through understanding biological and brain mechanisms that 
may underlie those relationships.
Moreover, just as correlations may be tight or loose, causation may 
also be strong or weak. Theoretically, we could claim a broad causa-
tion, akin to “smoking causes cancer,” with randomized prospec-
tive trials showing that children taking arts training can improve 
certain cognitive scores. Yet, even such a clear-cut result would be 
weak causation, because we would not have found even one brain 
mechanism of learning that could suggest progress in understanding 
such mechanisms to guide optimal arts exposure. Nor would we 
have found by what mechanisms the brain generalizes that learning, 
or anything about developmental periods during which the brain is 
particularly sensitive to growth from specific types of experience.
A vast area of valuable research lies between tight correlation and 
hard-evidence-based causal explanations. Theory-driven questions 
using cognitive neuroscience methods can go beyond efficacy-of-
outcome measures by framing experiments that demonstrate how 
changes in the brain, as a result of arts training, enrich a person’s 
life and how this experience is transferred to domains that enhance 
academic learning. Such mid-ground studies would significantly 
advance our knowledge even though they are not at the level of 
cellular or molecular explanations.
The consortium work on dance is a good example. Our research 
indicates that dance training can enable students to become highly 
successful observers. We found that learning to dance merely by 
watching can be highly successful and that the success is sustained at 
the neural level by a strong overlap between brain areas that are used 
for observing actions and also for making actual movements. These 
shared neural substrates are critical for organizing complex actions 
into sequential structure. In the future we can test whether this skill 
in effective observation will transfer to other academic domains.
Nailing down causal mechanisms in the complex circuitry of 
the brain is a tall order. The arts and cognition studies by the Dana 
consortium during the past three years laid a foundation for under-
standing the mechanisms needed for action; we believe they offer the 
validity essential for the future studies that will build on them.
A life-affirming dimension is opening up in neuroscience; to 
10
discover how the performance and appreciation of the arts enlarge 
cognitive capacities will be a long step forward in learning how to 
learn better and how to live more enjoyably and productively. We offer 
several suggestions for extensions of the research reported herein:
Previous work has established that different neural networks 1. 
are involved in various forms of the arts, such as music, visual 
arts, drama, and dance. Future studies should examine the 
degrees to which these networks are separate and overlap.
We also require evidence of how high motivation to pursue an 2. 
art form will lead to more rapid changes in that network, and 
we must find out to what degree such changes may influence 
other forms of cognition.
The links between music and visual arts training and specific 3. 
aspects of mathematics such as geometry need to be more 
profoundly explored with advanced imaging methods.
The link between intrinsic motivation for a specific art (e.g., 4. 
music and visual arts) and sustained attention to tasks involv-
ing that art needs to be followed up with increased behav-
ioral evidence and imaging methods that can demonstrate 
that changes in specific pathways are greater for higher levels 
of motivation.
The search for individual indicators of interest in and influence 5. 
by training in the arts should continue to be examined by a 
combination of appropriate questionnaire research, use of 
candidate genes already identified, and whole genome scans.
Further research also should pose these questions:
To what degree is the link between music training, reading, 1. 
and sequence learning causative? If it is causative, does it 
involve shaping connectivity between areas of the brain 
network involved?
Is the link between music and drama training and memory 2. 
methods a causative one? If so, can we use brain imaging to 
determine the mechanism?
What is the role of careful observation and imitation in 3. 
the performing arts? Can we prepare our motor system for 
complex dance movements by simply observing or imagining 
11
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desired movements? Do the discipline and the cognitive skill 
to achieve this goal transfer?
The consortium’s accomplishments to date have included bringing 
together some of the leading cognitive neuroscientists in the world 
to sort out correlative observations on the arts and cognition and 
to begin the analysis of whether these relationships are causal. The 
consortium’s new findings and conceptual advances have clarified 
what now needs to be done. The specific suggestions noted above 
grow out of the project’s efforts—and surely others are possible as 
well. These suggestions represent a further deepening of a newly 
accessible field of investigation. Fresh results as well as new ideas are 
presented herein on how to continue to research this topic.
In my judgment, this project has identified candidate genes 
involved in the predisposition to the arts and has also shown that 
cognitive improvements can be to specific mental capacities such as 
geometric reasoning; that specific pathways in the brain can be identi-
fied and potentially changed during training; that sometimes it is not 
structural brain changes but rather changes in cognitive strategy that 
help solve a problem; and that early targeted music training may lead 
to better cognition through an as yet unknown neural mechanism. All 
of those findings are rather remarkable and challenging.
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thE ExPANDiNG PotENtiAl 
of DEEP BRAiN StiMulAtioN
by Mahlon R. Delong, M.D., 
and thomas Wichmann, M.D.
introduction
During the last century, largely due to the absence of 
effective medical treatments, 
neurosurgeons, concerned to 
help desperate patients with 
disabling Parkinson’s disease, 
tremor, and other movement 
disorders, began to explore the effects of lesioning various brain 
structures. This practice reached a peak in the 1950s and 1960s, 
about the same time at which surgery for various psychiatric disorders 
and abnormal behavior was also peaking. After the introduction 
of levodopa replacement therapy for Parkinson’s in the 1960s, 
and in response to the strong public outcry against the excesses of 
psychosurgery, the use of neurosurgical interventions sharply declined 
during the following decades.
Against this backdrop, it may seem surprising that in the past 
decade there has been a virtual renaissance of neurosurgical treat-
ments for both neurological and psychiatric disorders. The most 
fundamental factor accounting for the resurgence of neurosurgical 
interventions has been the remarkable progress in basic science 
research into the organization of the motor system and the neurobiol-
ogy of disorders such as Parkinson’s disease. This research, carried 
out in primate models, has demonstrated that movement disorders 
such as Parkinson’s are the result of abnormal activity in discrete 
brain circuits, and that modulation of activity in these circuits through 
highly focused surgical interventions at several nodal points can 
effectively alleviate symptoms.1
Momentum for the resurgence of neurosurgical approaches comes 
14
from several factors: the available medications are not effective in 
treating all of the patient’s symptoms in advanced stages of many 
of these chronic neuropsychiatric disorders or they have unaccept-
able side effects, public awareness of the burden of these disorders 
on patients and their caregivers has increased, and, especially with 
respect to psychiatric conditions, patient consent procedures and 
other protections of patient rights are now consistently used.
Most of the targets for functional neurosurgical procedures 
that are in use today involve a cluster of brain structures called 
the basal ganglia. These subcortical brain structures are viewed as 
components of a family of anatomically distinct brain circuits that 
also encompass the cerebral cortex and thalamus. These circuits 
subserve aspects of motor behavior (“motor circuit”), cognitive/
behavioral function (“associative circuit”), and emotion and motiva-
tion (“limbic circuit”).
Broadly speaking, movement disorders such as Parkinson’s result 
from abnormal neuronal activity in the motor circuit, while abnor-
malities in limbic or associative circuits may underlie some of the 
symptoms and signs of neuropsychiatric conditions. Consequently, 
surgeries in movement disorder patients are generally aimed at targets 
within the motor circuit, while neuropsychiatric diseases are being 
treated with interventions aimed at the limbic or associative circuit.
In the new generation of surgical approaches, deep brain stimula-
tion (DBS) stands out for its ability to spark changes in the activity 
of certain circuits. DBS was first explored for movement disorders in 
the late 1970s as a treatment for tremor and was later found to be also 
highly effective for Parkinson’s disease and other movement disorders 
as more suitable targets were identified. In contrast to the irreversible 
effects of lesioning approaches, the brain is not permanently altered 
by DBS but is modified by the local application of electrical current 
in a way that can be changed or even reversed.
During DBS surgery, stimulating electrodes with four different 
contacts are implanted into specific brain regions, and a program-
mable pulse generator is implanted under the skin below the 
collarbone, similar to a cardiac pacemaker. The pulse generator can 
be programmed to deliver continuous stimulation of the optimal 
frequency, amplitude, and pulse duration to the targeted brain region. 
Reversibility and adjustability of stimulation are major advantages 
of DBS, as is its focused application in the relevant targets, which 
reduces the adverse side effects seen with drugs that act widely in 
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the brain.
Deep brain stimulation offers truly remarkable benefits to patients 
with advanced movement disorders and other conditions, but exactly 
why it works remains unclear. Scientists first believed it simply 
mimicked the effects of lesioning, but more recent studies of brain 
activity in animals and patients have suggested that DBS alters 
patterns of activity in the extended brain networks associated with 
the stimulated brain region by activating axons that leave or enter the 
stimulated region of the nucleus.
movement disorders
The most common application of deep brain stimulation is for 
patients with advanced Parkinson’s disease, a progressive disorder 
characterized by slowness of movement, tremor, and muscular rigid-
ity. The symptoms are caused by the loss of the neurotransmitter 
dopamine in the basal ganglia, which strongly affects the neuronal 
activity throughout the motor circuit.
While the early stages of Parkinson’s are amenable to medical 
therapy, the development of drug-induced involuntary movements 
called dyskinesias and the more rapid wearing off of medication 
limit the effectiveness of medication treatments in later stages of the 
disease. DBS within the motor portions of two basal ganglia nuclei, 
the subthalamic nucleus and the internal segment of the globus palli-
dus, reverses many of the motor problems of Parkinson’s, as well as 
the drug-induced complications.2,3 Major surgical complications are 
infrequent, occurring in 1 to 2 percent of patients, and the long-term 
benefits are substantial.
In addition to the subthalamic nucleus and globus pallidus, several 
alternative DBS targets are currently being explored, for instance the 
pedunculopontine nucleus, which shows some promise for severe 
cases of Parkinson’s disease with treatment-resistant gait and balance 
problems. DBS is also being used successfully in patients with move-
ment disorders other than tremor and Parkinson’s. For example, 
stimulation is now being tested in a variety of forms of dystonia, 
a highly variable movement disorder characterized by generalized 
or focal involuntary twisting movements and abnormal postures, 
bringing new hope to individuals who respond poorly to currently 
available treatments.4
16
neuropsychiatric disorders
Because of the remarkable success of deep brain stimulation for 
Parkinson’s disease and other movement disorders and the insight 
that several common neuropsychiatric conditions may be caused by 
similarly abnormal activity patterns in neuronal networks, neuro-
surgeons are now beginning to cautiously explore the use of DBS 
for several such conditions. At present, these procedures remain 
strictly experimental.
One promising area is the treatment of obsessive-compulsive disor-
der (OCD), a condition characterized by the presence of intrusive 
thoughts and compulsive behaviors. Neurosurgical lesioning treat-
ments for OCD have traditionally been aimed at empirical targets, 
such as the anterior limb of the internal capsule. It has recently been 
reported that DBS at the same target5 or in the nearby ventral striatum 
may also be beneficial.
Tourette’s syndrome, in which involuntary rapid, stereotyped 
movements and vocalizations (motor and vocal tics) are often associ-
ated with OCD, attention-deficit/hyperactivity disorder, depres-
sion, and psychosocial difficulties, may also be treatable with 
DBS.6 Because symptoms often remit after adolescence, treatment is 
reserved for severe cases that have not improved spontaneously. Based 
on earlier empirical lesion studies and consideration of the relevant 
limbic circuit anatomy, DBS at several surgical targets has been tested 
in these patients, including the midline intralaminar thalamic nuclei 
or the motor and limbic portions of the globus pallidus. The prelimi-
nary studies have demonstrated substantial symptomatic benefits in 
some cases.
Several studies are also now under way to evaluate the potential 
of DBS in patients with severe depression that is unresponsive to 
conventional therapies. Following imaging studies suggesting that 
the cortical subgenual cingulate region, also called area 25, may be a 
key structure in depression, a recent study reported that DBS in this 
area produces significant clinical benefits in patients with depres-
sion.7 With prolonged stimulation (for six months) a significant and 
sustained improvement was reported in two-thirds of the subjects, 
all of whom had failed multiple treatment trials. Needed now are 
follow-up studies and larger, well-controlled trials to try to confirm 
these findings and to gather data on other targets, such as the 
ventral striatum.
17
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Conclusions
Deep brain stimulation has become the neurosurgical procedure 
of choice for patients with disabling movement disorders and is 
currently also being explored for patients with a variety of severe 
neuropsychiatric disorders. Although the neurobiological bases of 
disorders such as OCD, Tourette’s syndrome, and depression are 
less well understood than those of movement disorders, a common 
element between these conditions seems to be that they are associated 
with brain circuit dysfunction, for which DBS may prove to be effec-
tive in patients with treatment-resistant symptoms.
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In 2007, scientists identified some of the genetic bases of autism spectrum disorders and attention-deficit/hyperactivity disorder—two of the most common developmental disorders. Researchers 
also began to lay the foundations for finding a potential cure for Rett 
syndrome, the most physically disabling of the autism spectrum disor-
ders, with which mostly girls are diagnosed because few boys survive 
past age 2, as well as fragile X syndrome, the most common inherited 
form of mental retardation, which occurs primarily in boys.
The Genetics of Autism
Although studies in twins have shown that autism spectrum disor-
ders are highly heritable, researchers have not been able to identify 
strong autism gene candidates so far. Moreover, the majority of people 
with autism have no family history of the disease, suggesting that 
inherited risk factors are quite complex. But in 2007, a team of scien-
tists led by Jonathan Sebat of Cold Spring Harbor Laboratory was 
able to gain some new insights into the genetics of these disorders.
In a paper published in Science in April, Sebat and colleagues 
reported that gene mutations called copy number variations, not 
present in either parent, appear to create a greater risk for autism 
than had been thought previously.1 These mutations typically involve 
deletions of tiny gene segments that arise spontaneously, rather than 
being inherited.
Sebat’s team looked for copy number variations in 264 families, 
including 118 “simplex” families with a single child with autism, 47 
“multiplex” families with multiple affected siblings, and 99 control 
families with no diagnoses of autism.
The investigators found that, among children with autism spec-
trum disorders who had no siblings with a disorder, 10 percent had 
gene-segment deletions, compared with 2.6 percent of children with 
autism spectrum disorders from multiplex families and 1 percent of 
the controls. These deletions occurred at many different sites in the 
genome. These data support the notion that spontaneously arising 
mutations in many genes are involved, and may in part explain why 
findings from previous genetic studies were inconsistent.
The fact that many genes may be involved in a disorder also suggests 
something fundamental about autism: perhaps the common features 
of autism (impaired social interaction, difficulty with communication, 
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and restricted interests and behaviors) owe their “commonality” not 
to common genes but to a common biological pathway involving a 
large and diverse set of genes.
The findings also have implications for the clinic. By screening 
children with autism spectrum disorders for spontaneous mutations, 
clinicians may be able to inform the parents about their risk of having 
a second child with an autism spectrum disorder—which is thought 
to be lower if a spontaneous mutation is present.
Attention-Deficit/Hyperactivity Disorder
Attention-deficit/hyperactivity disorder is characterized by several 
features: it is very common (affecting 3 to 7 percent of children), it is 
highly heritable, and it tends to ease in affected children as they get 
older. And a 2007 study may have homed in on one gene associated 
with the improvement in older children.
In a study published in August in Archives of General Psychiatry, 
Philip Shaw and colleagues at the National Institute of Mental Health 
investigated the effects of one of the most important known genetic 
risk factors for the disorder.2 The researchers studied a gene that 
Children with attention-deficit/hyperactivity disorder have a thinner cortex 
than those without, but brain scans (in which the numbers note the child’s 
age) show that, in the 30 percent of cases where ADHD is associated with a 
certain rare genetic variant, this gap is resolved by about age 16.
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is one of the rarer forms of the receptor for the neurotransmitter 
dopamine, called D4. Unlike other dopamine receptors, this receptor 
has a 7-repeat variant in a part of the gene called axon 3. This genetic 
variant accounts for about 30 percent of inherited cases of the disor-
der, making it by far the strongest candidate gene.
The researchers collected DNA, clinical data, and brain magnetic 
resonance images for 105 children with attention-deficit/hyperactivity 
disorder (ADHD) and 103 children without the disorder. An analysis 
of the data showed that, among children with attention-deficit/
hyperactivity disorder, possession of the 7-repeat gene was associated 
with both better clinical outcome and higher intelligence compared 
with children who did not have the 7-repeat gene. These findings were 
highly specific: no similar association with either a clinical outcome 
or a distinctive trajectory of cortical development was found with two 
other known genetic risk factors for ADHD.
The investigators also found that children who had the 7-repeat 
variant of this gene showed a distinctive pattern of cortical develop-
ment: the thickness of the cortex in areas important for the control of 
attention was initially thin, but then it thickened, converging with the 
development path of the healthy children by about age 16.
In a previous study, the same group of researchers reported that 
this pattern of cortical development was associated with better clinical 
outcomes in attention-deficit/hyperactivity disorder. The 2007 study 
linked genetics with both clinical outcome and cortical development, 
and it raises the hope that in the future, such genetic information 
could guide treatment efforts by clinicians.
Rett Syndrome Progress
Rett syndrome, caused by mutations in the gene methyl-CpG-
binding protein 2 (MeCP2), affects primarily girls. Symptoms develop 
in early childhood, resulting in impairments in speech, normal move-
ment, and hand use. Disordered breathing patterns and Parkinson’s-
like tremors are common.
Females with Rett syndrome have one mutated and one normal 
MeCP2 gene. Therefore, female mice with a stopped gene on one 
X chromosome are the best genetic model for this disorder. These 
mice develop Rett-like symptoms, such as tremors and problems with 
mobility and gait, between 4 and 12 months of age, and they then 
remain chronically symptomatic for an apparently normal life span.
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Although neurons show fewer branches than normal, there is 
no evidence for nerve cell death in either the mouse model or Rett 
patients (unlike neurodegenerative disorders such as Parkinson’s, 
Huntington’s, or Alzheimer’s disease). Because the faulty neurons 
remain alive, researchers at the Wellcome Trust Centre for Cell 
Biology at Edinburgh University in Scotland wondered whether 
restoring normal MeCP2 protein could rescue the nerves’ function 
and “cure” the mice.
In a study published in February in Science, Adrian Bird and 
colleagues tested this hypothesis by introducing a “stop-cassette” into 
the mouse MeCP2 gene, which prevented it from making MeCP2 
protein.3 The stopped gene could be reactivated at will by injecting 
the mouse with the drug Tamoxifen, which set in motion a sequence 
of molecular events culminating in deletion of the stop-cassette, 
thereby reactivating the MeCP2 gene to produce the protein.
The scientists waited until full-blown symptoms had developed in 
female mice before administering Tamoxifen. Strikingly, restoration of 
the MeCP2 gene to produce MeCP2 protein eradicated tremors and 
normalized breathing, mobility, and gait in mice that were sometimes 
only days away from death. In addition, female mice also recovered 
electrophysiological function, as measured by the ability of nerve cells 
to respond to stimulation.
Investigators also tried Tamoxifen in male mice after symptoms 
had developed. Again, most or all symptoms disappeared in male 
Adrian Bird, with colleagues 
at the Wellcome Trust 
Centre for Cell Biology in 
Scotland, manipulated the 
production of a protein 
called MeCP2 in a mouse 
model of Rett syndrome. 
They found that restoring 
MeCP2 production 
reversed symptoms. 
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mice with a restored MeCP2 gene, and these mice survived for an 
apparently normal life span.
These findings imply that the symptoms of Rett syndrome are 
potentially reversible, which may inspire similar research in related 
autism spectrum disorders.
Important Enzyme in Fragile X
A research group led by Nobel laureate Susumu Tonegawa at the 
Massachusetts Institute of Technology obtained similarly encouraging 
results regarding fragile X syndrome, the most common inherited 
form of mental retardation, which occurs primarily in males. Their 
research was published in the July Proceedings of the National 
Academy of Sciences.4
In the study, mice with a model of fragile X syndrome exhibited 
symptoms similar to those in human patients: hyperactivity, repeti-
tive movements, attention deficits, and difficulty with learning and 
memory tasks.
The experimental animals also had structural abnormalities that 
were similar to those found in humans. These males have a high 
number of dendritic spines in neurons in their brains, but each spine 
Mutations in the protein MeCP2 cause Rett syndrome. Mice bred with 
these mutations show elevated levels of a stress-control hormone called 
corticotrophin releasing hormone (CrH) in the hypothalamus, which is likely 
to contribute to the stress and anxiety that are Rett features.
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is longer and thinner than normal and transmits weaker electric 
signals than those in non-affected individuals. Dendritic spines are 
small protrusions on the branch-like dendrites of neurons that receive 
chemical signals from other neurons and communicate them to the 
main cell body.
The scientists hypothesized that inhibiting a certain enzyme in the 
brain could be an effective way to counter these structural changes, as 
well as the debilitating symptoms of fragile X syndrome. The enzyme, 
called p21-activated kinase, affects the number, size, and shape of 
connections between neurons in the brain.
The researchers found that halting the enzyme’s activity reversed 
the structural abnormality of neuronal connections in mice. Moreover, 
inhibiting the enzyme restored electrical communication between 
neurons in the brains of the mice, correcting their behavioral abnor-
malities in the process.
Because the expression of the gene that inhibits p21-activated kinase 
occurs after birth, it is possible that chemical compounds that inhibit 
the enzyme’s activity could one day be used to prevent or reverse 
mental impairments in young children with fragile X syndrome.
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Research into Huntington’s disease and Parkinson’s disease in 2007 brought the genetic and molecular underpinnings of these movement disorders more clearly into view but also 
revealed their dazzling complexity, thereby tempering excitement 
about treatment advances. Deeper understanding of both diseases 
depends on greater insights into the molecular activity taking place 
within brain cells, researchers say.
Huntington’s Disease
People who develop Huntington’s disease are born with the gene 
mutation that causes the disease, but many do not develop symptoms 
until they are in their forties. This long lag has puzzled scientists, but 
explanations have begun to emerge.
In one of the most provocative insights into Huntington’s disease 
during 2007, Cynthia T. McMurray and colleagues at the Mayo Clinic 
and elsewhere traced the disease process to the routine oxidation and 
repair of DNA, which has long been known to play a key role in the 
aging process itself.
Throughout life, oxygen atoms attach to nucleotides in the ribbon 
of DNA in each cell. Enzymes in the cell snip out those oxidized 
fragments and repair the DNA. In a paper in Nature, McMurray 
demonstrates that in people who carry the Huntington’s disease 
mutation, this process results in an expansion of the number of 
repeats of a sequence of three bases—cytosine, adenine, and guanine 
(CAG)—present at birth on chromosome 4.1 This sequence provides 
instructions for the manufacture of the huntingtin protein, crucial for 
transporting neurotransmitters from the cell body down the axon to 
the synapse, where communication between cells takes place.
Normally, people have between 10 and 35 CAG repeats on chromo-
some 4. People who have 40 or more CAG repeats eventually develop 
symptoms of Huntington’s, and the greater the number of repeats, the 
earlier symptoms tend to appear. For example, a child with 95 repeats 
developed seizures, cognitive decline, and neuromuscular disorders 
by the age of 3 and died of Huntington’s disease at age 11.
The normal repair of DNA tends to increase the number of 
CAG repeats, according to McMurray. She blames this effect on a 
single enzyme known as OGG1, which causes neurons to produce 
an increasingly toxic form of the huntingtin protein containing too 
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much glutamine, an amino acid crucial for cell metabolism. The 
extra glutamine makes the huntingtin protein sticky, causing it to 
clump together and create debris within the nucleus. This leads to a 
cascade of cell dysfunction that eventually produces the symptoms of 
Huntington’s disease.
This observation coincides with the linear relationship between 
the number of CAG repeats and the age of disease onset. Those 
born with a large number of CAG repeats develop symptoms early, 
whereas those born with a smaller number of repeats do not develop 
symptoms until this DNA repair process has had time to expand the 
number of CAG repeats to a more toxic level.
In mice that lack the OGG1 enzyme, CAG expansion was power-
fully suppressed with no ill effects, suggesting that DNA repair could 
be carried out by “backup” enzymes. Thus, this enzyme appears to 
be specifically responsible for promoting CAG expansion, suggesting 
that if OGG1 somehow could be blocked in humans, the damage 
caused by Huntington’s disease could be significantly postponed or 
even prevented.
Taking a different approach, researchers at Cambridge and Harvard 
have attempted to mitigate the toxic effects of mutant huntingtin 
protein by coaxing cells to remove toxic debris more efficiently.
In a paper published in Nature Chemical Biology, Stuart L. 
Schreiber, David C. Rubinsztein, and colleagues report that adminis-
tering what they call “small-molecule enhancers” to yeast stimulates 
autophagy, a process by which cells dispose of defective and misfolded 
proteins such as mutant huntingtin.2 If autophagy could be stimulated 
in people with Huntington’s disease, it would do nothing to slow or 
stop the production of huntingtin, but by clearing toxic debris from 
the cells more effectively, it might postpone the onset of symptoms, 
the researchers believe.
Brain scans show the 
dramatic difference 
between a healthy 
individual (left) and 
one with Huntington’s 
disease (right).
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But mutated huntingtin protein appears to cause numerous other 
problems, which Elena Cattaneo and colleagues at the University of 
Milan are studying.
For example, normal huntingtin stimulates the production of 
brain-derived neurotrophic factor (BDNF), a protein that supports 
existing neurons and encourages the growth of synapses and new 
neurons. In people with Huntington’s disease, neurons in the striatum 
die, producing spasticity and many other symptoms. In 2001 Cattaneo 
and colleagues demonstrated that levels of BDNF are known to be 
lower in people with Huntington’s.3
In 2007, they expanded on that discovery by attributing the 
dysfunction to a genetic regulatory site that affects BDNF in people 
with Huntington’s disease.4 However, the site is located in a region of 
more than 1,000 genes that affect more than just BDNF, suggesting 
that other genes that affect neurons may be dysfunctional in people 
with Huntington’s. Currently Cattaneo’s team is looking for molecules 
that will mimic the activity of normal huntingtin and increase the 
expression of BDNF and related genes. So far they have identified 
three compounds that increase the production of BDNF in cells 
affected by Huntington’s disease.5
BDNF also appears to regulate the development of synapses by 
increasing the amount of cholesterol in synaptic vesicles.6 In 2005, 
Cattaneo and colleagues found that cells and tissues in people with 
Huntington’s had too little cholesterol and that adding cholesterol 
to the striatal neurons most affected by the disease prevented their 
death.7 In a 2007 paper in Human Molecular Genetics, Cattaneo and 
colleagues report that mice with a model of Huntington’s disease also 
show a lack of cholesterol, and they attribute this deficiency to the 
same mutant huntingtin protein found in people with Huntington’s.8
The researchers suspect that BDNF signaling directly affects 
cholesterol biosynthesis, a hypothesis that unifies two seemingly 
separate dysfunctions.
And while a cure for Huntington’s disease must await a form 
of genetic engineering that will fix the DNA repeats that result in 
Mice with a model of Huntington’s disease show a lack of 
cholesterol, and researchers attribute this deficiency to the same 
mutant huntingtin protein found in people with Huntington’s.
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faulty huntingtin protein, a recent study in mice found that a small 
molecule known as C2-8 may inhibit the aggregation of mutant 
huntingtin within cells, which would at least slow the development 
of symptoms.9
Parkinson’s Disease
Researchers developed two novel ways to treat Parkinson’s disease 
in 2007, raising hopes of at least alleviating symptoms such as tremors 
and muscle rigidity.
Researchers at Northwestern University reported in Nature that 
they could “rejuvenate” dopamine-producing neurons in a brain 
region called the substantia nigra pars compacta. These neurons die 
in people with Parkinson’s, thereby depriving the brain of enough 
neurotransmitter to maintain normal movement.10
These cells ordinarily use calcium channels to maintain normal 
metabolism. However, James Surmeier and colleagues found that 
mice bred without calcium channels functioned normally because 
their dopamine-producing cells continued to use their sodium chan-
nels, which are normally active only in youth.
They applied isradipine, a calcium channel inhibitor, to block the 
calcium channels in neurons taken from normal mice. For about 30 
minutes the cells ceased functioning. Then they resumed their pace-
making activity as the dormant sodium channels began functioning 
again. When the researchers implanted pellets of isradipine below the 
skin in mice bred to have symptoms of Parkinson’s disease, the mice 
did not develop the motor deficits characteristic of the disease.
Further evidence that isradipine may be helpful comes from the 
fact that it belongs to a class of drugs used to treat hypertension. A 
retrospective study suggests that patients with hypertension treated 
with these drugs have a lower incidence of Parksinson’s.11
A failure of the mitochondria, the energy-producing vesicles inside 
of cells, is another possible cause of the breakdown of dopamine-
producing neurons. Researchers at Stanford showed that a mutation 
in a gene known as pink1 correlates with a higher incidence of 
Parkinson’s disease.12 When they bred fruit flies with this mutation, 
the fruit flies’ flight muscles, as well as their dopamine-producing 
neurons, degenerated.
The muscle degeneration was preceded by abnormalities in the 
mitochondria, which produce energy for the cell. Mitochondrial 
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dysfunction has been suspected in Parkinson’s disease, the authors 
say, because pesticides known to increase the risk of the disease 
inhibit mitochondria. However, flies bred to overexpress parkin, 
a protein involved in the clearing of misfolded proteins, did not 
develop these problems, suggesting that pink1 and parkin operate 
in a common pathway that regulates mitochondrial function and cell 
survival in fruit flies.
In the realm of treatment, research in 2007 suggested hope for gene 
therapy. In the first gene therapy study for Parkinson’s, it produced 
significant improvement with no ill effects.13 Researchers at New 
York–Presbyterian Hospital/Weill Cornell Medical Center implanted 
a harmless virus bearing a gene for an enzyme called glutamic acid 
decarboxylase (GAD) into 12 patients. GAD produces GABA, a 
neurotransmitter that quells excessive neuronal firing and promotes 
coordinated movements.
The harmless, GAD-bearing virus was implanted in the subtha-
lamic nucleus at the center of the brain, which regulates movement, 
in hopes of boosting the production of GABA and thereby restor-
ing normal function, according to lead author Michael Kaplitt. 
(In 2003, Kaplitt performed the world’s first gene therapy surgery 
for Parkinson’s.)
Yu-Hung Kuo, left, watches as Michael Kaplitt of New York–Presbyterian 
Hospital/Weill Cornell Medical Center prepares to infuse an enzyme in hopes 
of improving movement in patients with Parkinson’s.
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To minimize possible risk, the harmless virus was implanted in 
only one side of the brain, but because patients have symptoms on 
both sides of their body equally, this technique also provided a way to 
recognize and measure improvement. Three months after the surgery 
the patients as a group showed a 25 to 30 percent improvement in 
movement according to the Unified Parkinson’s Disease Rating Scale. 
Some showed improvement of 40 to 65 percent.
Such impressive improvement puts interest in this potential 
therapy in the company of deep brain stimulation, which is already 
widely used to control the gait disturbances and movement problems 
of Parkinson’s disease (see also Neuroethics, page 45) in patients to 
extend the window of therapeutic effectiveness.
Deep brain stimulation holds out the greatest immediate promise 
for Parkinson’s patients. The therapy involves implanting electrodes 
deep within the brain, in a region called the subthalamic nucleus. 
These electrodes are then stimulated to modify electrical communica-
tion of nerve cells within and among brain circuits. Through this 
process, deep brain stimulation blocks the uncontrolled signals that 
produce the motor symptoms of Parkinson’s, especially tremor.
In 2007 researchers in Italy expanded upon deep brain stimulation 
by placing electrodes in a new area, the pedunculopontine nucleus, 
that plays an important role in walking.14 Six patients with Parkinson’s 
who had not responded well to medication safely responded to 
electrodes that stimulated the pedunculopontine nucleus at 25 Hz 
and the subthalamic nucleus at 185 Hz. Patients improved overall by 
more than 60 percent as measured by the rating scale—well above 
the improvement achieved by stimulation of either brain area alone, 
or by medication.
Deep brain stimulation is now an approved and accepted therapy 
in Parkinson’s disease patients whose symptoms can no longer be 
treated with L-DOPA, or whose side effects from long-term L-DOPA 
medication have become debilitating.
For deep brain stimulation, scientists continue to study where 
in the brain electrodes will alleviate symptoms most effectively. 
Another recent study found that deep brain stimulation may even 
have a neuroprotective effect on the dopamine-producing cells in the 
substantia nigra that degenerate in the disease.15
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Nervous system injuries comprise a diverse group of disorders affecting the brain and spinal cord, including stroke, spinal cord injury, and brain tumors. In 2007, researchers reiterated the 
importance of acting quickly after stroke, tried new approaches to treating 
brain tumors, and worked to improve clinical trials in spinal cord injury.
Act Quickly After Stroke
Getting to a hospital in time and getting the right care once there 
continue to dominate the news in clinical research of stroke, and new 
data from Europe extend the urgency to the follow-up care of people 
with transient neurological symptoms as well.
In May, the American Heart Association and the American Stroke 
Association updated their acute-care guidelines for stroke, reaffirm-
ing top billing for tissue plasminogen activator (tPA), the anti-clotting 
agent that should be given within three hours of stroke onset in order 
to minimize brain damage after ischemic stroke.1 (Ischemic stroke is 
caused by a lack of oxygen to the brain, typically due to a blockage in 
arteries that feed blood to the brain.) The guidelines also urged better 
preparedness for rapid response by hospital emergency rooms and 
first responders; new data from the Centers for Disease Control and 
Prevention show that fewer than half of stroke patients reach hospi-
tals within two hours of the onset of acute neurological symptoms.2
While a major stroke is often marked by overt symptoms, such as 
blurred vision, slurred speech, or numbness or paralysis in one side of 
the body, some brain effects of ischemia are temporary and leave no 
clinically detectable signs. These are referred to as transient ischemic 
attacks. Brain imaging studies of patients who have had temporary 
neurological symptoms show evidence suggestive of such transient 
attacks. Once a transient ischemic attack occurs, the underlying cause 
likely persists and may eventually cause a major stroke, unless treated 
appropriately. Transient ischemic attacks, therefore, are important 
risk factors for major stroke.
Interventions following a transient ischemic attack are aimed at 
preventing additional strokes in the weeks and months afterward. A 
large base of evidence now suggests that reducing stroke risk factors, 
such as high blood pressure and elevated cholesterol, can prevent 
strokes. Two papers published in October point to the importance of 
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initiating such therapies immediately in people who have suffered a 
transient attack.
The first, by neurologist Peter Rothwell and colleagues at the 
University of Oxford, England, and published in Lancet, found that 
patients who were treated with existing preventative therapies within 
24 hours of a transient ischemic attack had a dramatically reduced risk 
of developing a serious stroke in the next three months, compared with 
patients who did not receive immediate follow-up care.3 Specifically, 
the risk of a recurrent stroke was cut from 10 percent to 2 percent, 
an 80 percent reduction, which the authors said could translate to the 
prevention of 10,000 strokes a year in the United Kingdom alone. The 
study examined about 600 people, drawn from a larger Oxford study 
that is tracking the incidence of stroke and transient ischemic attack 
in nearly 100,000 people.
A second study, published in Lancet Neurology and led by stroke 
neurologist Pierre Amarenco of Bichat-Claude Bernard University 
Hospital in Paris, also affirmed the benefit of early intervention to 
prevent strokes.4 The researchers evaluated 1,085 patients with a 
suspected transient ischemic attack who were admitted to a 24-hour 
hospital clinic. Urgent assessment included imaging of the brain, 
blood vessels, and heart. Patients with confirmed or possible transient 
ischemic attacks were immediately put on a preventative therapeutic 
regimen, which typically involved drugs to reduce blood pressure 
and/or cholesterol and aspirin to reduce blood clotting.
About 5 percent of patients underwent procedures to open the 
carotid artery, the main artery in the neck that feeds blood to the 
brain. These patients underwent either open surgery (carotid endart-
erectomy) or trans-arterial placement of a stent to expand the carotid 
artery (endovascular therapy). Another 5 percent who had atrial 
fibrillation, a disturbance of the rhythm of the heartbeat, were given 
anticoagulant drugs to reduce the risk of blood clots forming in the 
heart due to this condition. Such clots can travel from the heart to the 
brain and cause a stroke.
Among patients who were treated early, the rate of stroke in the 
90-day period after the transient ischemic attack was just over 1 
percent, compared to an expected rate of nearly 6 percent based on 
previous observational studies. Taken together with the Lancet report, 
the findings prompted experts worldwide to urge a new standard of 
care for patients suffering transient ischemic attacks, emphasizing 
urgent assessment and treatment to prevent stroke.
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Targeting Brain Tumors with Molecular Precision
While brain tumors continue to evade effective treatment 
approaches, much of the current anticipation relates to the develop-
ment of molecularly targeted therapies to attack tumors, as is true 
in cancer research overall. There is also a growing appreciation 
that no one therapy may be enough to eradicate the most lethal 
brain cancers, leading to increasing investigation of combination 
approaches that add newer therapies to standard treatments such as 
radiation and chemotherapy.
Many researchers are convinced that such multimodal therapies 
offer the best hope for people facing a diagnosis of malignant glioma, 
a family of brain tumors that, though relatively rare, have high death 
rates within a short period following diagnosis. Glioblastoma multi-
forme, one of the most aggressive members of this family, has been 
particularly difficult to treat.
Clinical research in this area is being driven by new understand-
ing about the pathogenesis of tumor development at the molecular 
level as scientists unravel the specific signaling factors and pathways 
that tumors use to grow and spread. Differences among tumors 
are negating a “one-size-fits-all” approach to treatment. Still, there 
appear to be commonalities in some elements of the pathways tumors 
use, and researchers are focusing many of their efforts on these 
common features.
One promising avenue is to starve tumors of their blood supply, 
an approach that is being investigated for many types of cancer. In 
January 2007, Rakesh Jain and colleagues from the Massachusetts 
General Hospital Cancer Center reported preliminary results in 
Rakesh Jain and colleagues 
at Massachusetts General 
Hospital Cancer Center 
studied a drug that tamps 
the growth of brain-tumor 
blood vessels.
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Cancer Cell of an investigational drug that suppresses the growth 
of blood vessels that feed tumors.5 This drug, AZD2171, blocks the 
three primary receptors for VEGF, a powerful blood vessel growth 
promoter known to be present on vessels that feed glioblastoma 
tumors. (Mature blood vessels in normal tissue do not rely on VEGF 
for survival.)
Results from a Phase 2 clinical trial in 16 patients with recurrent 
glioblastoma who were treated with AZD2171 found that tumors 
The experimental drug shows promise in brain scans of the most responsive 
test patient. The numbers at the top correspond to days before or after 
starting treatment. The top row shows the tumor shrinking over time. Other 
rows show drops in tumor blood-vessel size, the permeability of the blood-
brain barrier, and swelling in regions around the tumor. The last row shows 
white matter visibility as swelling subsides.
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shrank by 50 percent or more in half of the patients, and by at least 
25 percent in three-quarters of the study participants. Brain imaging 
showed a rapid effect on the normalization of blood vessels, begin-
ning after just one dose of the medication in some patients, and a 
decrease in brain swelling, a common problem in brain cancer. The 
trial is continuing, and the researchers hope to also investigate the 
drug in combination with traditional cancer therapies in people newly 
diagnosed with glioblastoma.
Researchers at Duke University have combined another blood 
vessel inhibitor, bevacizumab (Avastin), with the chemotherapeutic 
drug irinotecan in a Phase 2 trial of 32 patients with advanced glioma. 
Preliminary results, published in Clinical Cancer Research in February 
2007 by James Vredenburgh and colleagues, suggest that the combi-
nation is active against this lethal form of tumor and has “acceptable” 
toxicity.6 In nearly two-thirds of the patients, tumors shrank by at 
least 50 percent, and at six months, tumors had not started to regrow 
in 38 percent of the patients. In contrast, chemotherapy alone typi-
cally slows glioma growth for just six weeks to three months.
Vredenburgh and other brain tumor experts say the key to 
improving treatment for malignant gliomas lies in better determining 
which patients are most likely to respond to specific therapies and in 
improving combinatory approaches to treatment. They also point to 
the need for improving clinical trial designs to obtain the maximum 
amount of information in the shortest period of time.
Spinal Cord Injury:  
Paving the Way for Clinical Trials
Better clinical trial design also has been a focus in spinal cord 
research, as work in this area advances toward the translation of 
basic science findings into therapeutic approaches. In March 2007, 
an international multidisciplinary panel of researchers published the 
Brain tumor experts say the key to improving treatment for 
malignant gliomas lies in better determining which patients are 
most likely to respond to specific therapies and in improving 
combinatory approaches to treatment.
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first guidelines for clinical trials in spinal cord injury in a series of four 
papers in Spinal Cord.7–10
The effort, by the International Campaign for Cures of Spinal 
Cord Paralysis, is an attempt to delineate criteria for robust, realistic, 
and useful clinical trials for anticipated therapeutic options that are 
currently being tested in preclinical investigations. The panel called 
for rigorous and standardized attention to outcome measures, inclu-
sion and exclusion criteria, and ethics in designing and conducting 
human research trials.
For example, the authors said that outcome measures should 
include anatomical and neurologic assessment to demonstrate “recon-
nection” of the spinal cord, measures of patients’ ability to engage in 
activities of daily living, and quality-of-life measures. With respect to 
inclusion/exclusion criteria, the panel said that patients participating 
in studies should be at stages of injury where there are data from 
animal studies or previous human studies to support a potential 
benefit of intervention, and that the severity, level, type, and size of 
their injury should be considered in relation to the likelihood that an 
experimental treatment would benefit them. Study participants must 
provide informed consent based on a clear, adequate explanation of 
the risks, benefits, and scientific rationale of investigational therapies, 
the authors said.
Prospective, double-blind, randomized trials utilizing appropriate 
control participants are optimal, the group said, while recognizing that 
in some situations, other trial procedures may have to be considered.
The guidelines appear to be prompted in part by the frustration of 
Western scientists trying to evaluate the effectiveness of uncontrolled 
human research. In a field where no treatment is known to be effec-
tive, patients and their families have been desperate for a treatment for 
spinal cord injury. As a consequence, they and some researchers have 
been willing to try anything. This has become a particular problem in 
countries where regulations governing clinical research are lacking, 
including China, where scores of unproven stem cell transplants are 
being done in spinal cord–injured patients. The panel also seeks to 
avoid clinical trial design problems that have plagued the develop-
ment of treatments for other complex neurological problems—
notably the lack of sufficiently sensitive outcome measures in clinical 
trials investigating new neuroprotective therapies for stroke.
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The ethical implications of the many rapid advances in neuro-science continue to feed the growth of neuroethics, which is taking an increasingly prominent place in the larger field of 
bioethics. In 2007, the American Journal of Bioethics began publishing 
twelve issues instead of six, in part to devote a full three issues per 
year to neuroethics. These special issues, called AJOB Neuroscience, 
are now the official journal of the Neuroethics Society.
Four main developments have stirred discussion and debate in 
neuroethics this past year: commercialization of lie detection, propos-
als to use deep brain stimulation for treating depression, advances in 
the genetic understanding of addiction, and improvements in brain 
imaging for diagnostic purposes.
Commercialization of Lie Detection
In recent years, advances in the ability to use functional magnetic 
resonance imaging (fMRI) to map activity in different brain regions 
fueled research into using the technology for detecting lies. And 
though the research is still preliminary and the results problematic, 
two companies have rushed to develop fMRI-based lie-detection 
products and services: Cephos Corporation and No Lie MRI. The 
companies say potential uses include crime investigations, parole 
and child-custody hearings, counterintelligence, and insurance and 
government security interrogations.
In 2007, the American Journal of Law and Medicine published a 
paper, coauthored by Henry Greely of Stanford and Judy Illes, now 
of the University of British Columbia, that analyzed existing research 
on fMRI-based lie detection and made an urgent call for regulation.1 
Judy Illes has called for 
regulating lie detection that is 
based on functional magnetic 
resonance imaging, in a paper 
she coauthored with Henry 
Greely. Studies of the technology 
have not proved it reliable, the 
authors say. 
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The authors argue that while the technology is promising, the existing 
studies do not prove it to be reliable with any accuracy in the real 
world, particularly given the artificial and trivial nature of the lies 
tested in these experiments.
What’s more, none of these small-scale studies have been repli-
cated by outside investigators, nor did the studies look at the possibil-
ity of subjects’ using countermeasures to outwit the lie detectors. The 
authors’ proposed regulatory scheme, modeled after the way the FDA 
controls the use of drugs, would require marketers of lie-detection 
technology to prove that it is accurate and effective based on large-
scale trials. Under this system, marketing the technology without 
regulatory approval would be illegal.
Illes also coauthored (with Margaret Eaton of Stanford) a commen-
tary in the April 2007 Nature Biotechnology discussing some of the 
ethical, social, and policy issues associated with the commercialization 
of cognitive neurotechnology in general.2 These concerns include 
accuracy, brain privacy and confidentiality, and potential conflicts of 
interest for the people bringing these technologies to market.
One danger of an unregulated lie-detection industry is the 
exploitation of the most vulnerable members of the population, such 
as those suffering from neurologic or psychiatric disorders. Yet our 
society seems so eager for lie-detection devices that many people are 
quick to accept claims that they work, the authors stress.
Deep Brain Stimulation for Severe Depression
Following the success of using deep brain stimulation (DBS) 
to treat physical symptoms of Parkinson’s, and following imaging 
research that identified a specific brain region involved in depression 
that might be treated with deep brain stimulation, researchers began 
clinical trials of this technique in a small number of patients with 
intractable depression. Findings of remarkable symptomatic relief in 
many of these surgical patients were published in 2005, but in 2007 
the treatment began to receive ethical scrutiny.
Given the relative newness of using deep brain stimulation, even 
for treating Parkinson’s disease, researchers are learning more about 
unanticipated risks. In June 2007, Acta Neuropsychiatrica published 
a case report documenting how slight adjustments in the electrode 
contact or voltage in two Parkinson’s patients induced life-threatening 
(suicidal) depression.3
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Questions of safety are always important, but people tend to accept 
significant risk in treating debilitating and sometimes deadly diseases 
such as Parkinson’s, researchers say. Depression is far more controver-
sial: some patient advocacy groups believe it is overdiagnosed; some 
say that even if it is real sufferers should learn to cope with it, and still 
others cite the existence of many antidepressant drugs.
However, deep brain stimulation is meant for intractable depres-
sion, the sort that doesn’t respond to drugs. And, lacking effective 
treatment, patients can be debilitated and are sometimes at risk for 
suicide. Deep brain stimulation for depression and other clinical uses 
currently lacks clinical-trial guidelines, and in 2007 a group of leading 
DBS researchers participated in a consensus development meeting to 
draft guidelines for experimental use of DBS in patients.
Another ethical concern is informed consent. The impaired 
cognition and desperation that can accompany severe depression 
may greatly compromise patients’ judgment. Hovering over the 
whole debate is the specter of electroconvulsive shock therapy, 
whose therapeutic benefits are not disputed, but whose use remains 
enormously controversial.
Genetic Underpinnings of Addiction
Several scholarly articles on genes that may underlie addiction were 
published in 2007. For example, Colin Haile and colleagues published 
an article titled “Genetics of Dopamine and Its Contribution to 
Cocaine Addiction” in Behavior Genetics.4 Joel Gelernter and 
colleagues published “Genomewide Linkage Scan for Nicotine 
Dependence: Identification of a Chromosome 5 Risk Locus,” which 
appeared in Biological Psychiatry.5
For alcoholism, according to a commentary by Charles O’Brien6 
published in the November 2007 issue of Addiction, there is increasing 
evidence that a variant of the gene for the brain’s mu opiate receptor 
is associated with increased sensitivity to alcohol euphoria, increased 
risk of alcoholism, increased risk of opiate addiction, and good clini-
cal response to the drug naltrexone for alcoholism in clinical trials.
Evidence suggesting that genes predispose some individuals to 
addictive behaviors raises ethical questions.
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Evidence suggesting that genes predispose some individuals to 
addictive behaviors raises ethical questions. One set of questions 
revolves around testing. If certain genes contribute to addiction but 
don’t determine it with certainty, should we test for them at all? How 
much predictive power, or value for selecting a treatment, must the 
genes have before we do decide to test for them? How early should 
testing begin? Learning that a child is prone to nicotine addiction, 
for example, might enable parents to take necessary precautions, 
such as extra education and protection from cigarette ads—or this 
knowledge might lead to overparenting and unnecessary parental 
anxiety. Knowing about one’s own propensity toward addiction also 
could become a self-fulfilling prophecy. Additionally, knowledge of 
predisposing genes, once addiction is diagnosed, would be valuable 
in selecting the most appropriate treatment.
Counseling raises additional questions: What should a doctor say 
to a parent whose child has genes that make the child more likely to 
become a smoker, alcoholic, or heroin addict? The question becomes 
even thornier if genetic information is available in utero; some parents 
might reconsider whether they want the pregnancy.
Advance knowledge of propensity toward addiction also raises 
questions of whether anti-addictive drugs (such as naltrexone) should 
be given prophylactically, before addiction actually develops. Given 
the high costs of treating addiction, prospective employers and insur-
ance companies might have a strong vested interest in testing—and 
could discriminate against carriers of the genes. (Laws currently do 
prevent unauthorized disclosure of genetic information to insurers 
and employers.)
Social stigma is another consideration, just as for any genetic 
abnormality. Mere carriers may have a harder time finding marriage 
and reproductive partners, and parents may feel guilty for passing 
on bad genes, even if the child shows no sign of actual addiction. 
Discussion around these questions is bound to heat up as we learn 
more about the genetic risk factors for addiction.
Brain Imaging for Diagnostic Purposes
While the use of brain imaging for diagnosing most psychiatric 
disorders is still a distant prospect, there were strides in 2007 in the 
experimental use of specific imaging compunds that may identify 
people with early Alzheimer’s and other forms of dementia. In August 
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2007, Agneta Nordberg published a review article in Current Opinion 
in Neurology7 discussing a new amyloid imaging technique using 
positron emission tomography that shows clear differences between 
the brains of Alzheimer’s patients and healthy controls. This study 
suggests that early diagnosis of Alzheimer’s disease may be possible. 
Similarly, a case study published in the March 2007 issue of the 
Archives of Neurology8 reported successful use of the imaging agent 
Pittsburgh Compound B to spot mild cognitive impairment.
Studies such as these give hope that imaging will help provide 
more precision for diagnosing anxiety disorders and autism spectrum 
disorders, once the biological bases of these disorders are better 
understood. But the hottest area in the search for better diagnosis is 
with limited states of consciousness, especially in accurately differen-
tiating people who are in a permanent vegetative state from those who 
are in a minimally conscious state.
While no major technical strides were made in this area in 2007, 
the ethical framework continued to develop. In June, Judy Illes and 
Joseph Fins led a well-attended workshop at Stanford University, 
“Ethics, Neuroimaging, and Limited States of Consciousness,” at 
which scholars discussed these issues. They reached agreement on 
several aspects of them, including research and clinical goals for 
carrying out neuroimaging studies of patients in limited states of 
consciousness, concerns about obtaining informed consent or autho-
rization for such studies, and experimental protocols such as ethically 
coherent approaches to selecting candidates and designing tests. A 
special issue of American Journal of Bioethics Neuroscience dedicated 
to this topic is forthcoming.
But even as neuroethicists reach consensus on these questions, and 
although imaging will undoubtedly continue to improve, researchers 
and clinicians continue to debate the much trickier questions of 
how to interpret the brain images and what their prognostic value 
is in patients with disorders of consciousness. In an April article 
in Neurology, Joseph Fins, Nicholas Schiff, and Kathleen Foley 
recommended trying to define the epidemiology of the minimally 
conscious state, clarify mechanisms of recovery, and identify clinically 
useful diagnostic and prognostic markers to aid decision making at 
the bedside.9
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The immune system employs its large and varied arsenal of interdependent cells and their molecules to protect us from a constant onslaught of disease-causing organisms. If improp-
erly targeted or regulated, however, the cells and molecules of the 
immune system may themselves cause disease.
Although it is not clear why, the immune system appears to be 
the aggressor in the neurological disease multiple sclerosis. Immune-
mediated damage to the insulating coating of nerve cells’ axons in the 
brain and spinal cord interferes with transmission of nerve impulses 
from one cell to another. Multiple sclerosis can cause a variety of 
symptoms, ranging from vision disturbances to difficulty walking, 
and it often follows an up-and-down course in which symptoms 
periodically worsen.
Both genes and the environment affect susceptibility to multiple 
sclerosis, but it is likely that many different genes and many different 
environmental influences interact in the development and progression 
of disease. Research in 2007 provided new evidence of contribu-
tions by genetic and environmental factors that work through the 
immune system.
Converging on the IL-7 Receptor
In 1972, the genetics involved in multiple sclerosis risk were first 
linked to a group of immune system genes called HLA. Since then 
there has been relatively little progress in identifying additional 
specific genetic risk factors. But the publication of the sequence of the 
human genome (the complete set of DNA instructions in each human 
cell) in 2001 has allowed for huge advances in genetic analyses. Using 
new laboratory techniques and powerful computers, researchers can 
now analyze previously inconceivable amounts of data, looking for the 
elusive needle in the genomic haystack.
Of the 3 billion base pairs in the human genome, most of the varia-
tion is limited to 250,000 to 500,000 segments of DNA. Simultaneous 
scanning of these many segments is possible with DNA microarrays, 
or “gene chips.” Genome-wide scans have revealed genes associated 
with breast cancer, heart disease, and diabetes.1 These scans require 
large sample numbers to reveal statistically significant associations 
when multiple genetic factors each have a small effect. (For more 
on “genome-wide association,” see also Psychiatric, Behavioral, and 
Addictive Disorders, page 63.)
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for multiple sclerosis were published in the August 30 issue of the 
New England Journal of Medicine.2 An international consortium of 
investigators used gene chip technology to examine hundreds of 
thousands of individual genetic changes in a total of more than 12,000 
samples. Without any preconceived ideas of what they would find, 
the investigators confirmed the link between the HLA region and 
the disease and teased out two other markers, one in the gene for 
the interleukin-2 (IL-2) receptor and one for the interleukin-7 (IL-7) 
receptor. Interleukins are immune system proteins through which 
cells communicate and affect the function of other cells.
These receptors are important for cell-to-cell signaling in the 
immune system. Like the proteins associated with the HLA gene, 
the IL-2 and IL-7 receptors are important regulators of the immune 
system, so it makes sense that the genes that produce these two 
interleukin receptors might play a role in multiple sclerosis. However, 
no attempt was made in this study to show anything beyond a 
statistical association.
Often, genetic studies will turn up several possible genetic risk 
factors for a particular disease, none of them very strong. Subsequent 
efforts to confirm such risk factors often fail. Now, by combining 
several different experimental approaches in what Michael Hauser 
of the Center for Human Genetics at Duke University dubbed 
“genomic convergence,” scientists can home in on the most promising 
gene candidates.
A stronger case for a genetic marker can emerge from combin-
ing results of studies associating genes with disease within families, 
A DNA microarray, or 
“gene chip,” has helped 
reveal genetic risk factors 
for multiple sclerosis.
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analyzing how genes are inherited together and examining which 
genes are active in affected tissues. This approach has been used 
to study the genetics of several complex neurological diseases, 
including Parkinson’s disease and Alzheimer’s disease, as well as 
multiple sclerosis.
As part of a genomic convergence approach to the last, two 
studies appearing in the September 2007 issue of Nature Genetics 
used targeted searches to look at candidate genes, those that had 
shown promise in previous functional and genetic studies.3, 4 Like 
the genomic scan, the Nature Genetics studies also implicated the 
IL-7 receptor. In fact, they identified the same single-base variation 
(single-nucleotide polymorphism, or SNP) in the gene that produces 
the IL-7 receptor.
This particular genetic variation was predicted to make it less 
likely that the receptor will be bound to the cell membrane, where it 
can perform its signaling function, and more likely to be present in 
soluble form, where it can bind up IL-7 and keep it from interacting 
with cells. Indeed, this was the case, both in the laboratory and in 
Hybridized DNA fragments glow when a laser light is shined on a microarray, 
which contains many millions of fragments.
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people with multiple sclerosis. This change would theoretically reduce 
the effect of IL-7 in the body. In addition, expression of genes for 
both IL-7 and the IL-7 receptor were altered in the cerebrospinal 
fluid of people with the disease.
Evidence continues to accumulate that IL-7 and its receptor play 
an important role in the disease process, though it is not clear how. 
The increase in disease risk attributed to the IL-7 receptor gene is 
small, but the IL-7 receptor is getting harder and harder to ignore. 
Further study of the IL-7 receptor may reveal its role in multiple 
sclerosis and provide new approaches to treatment.5
An IL-7-based pathway in the disease process would be but one of 
many different disease-promoting mechanisms. Analysis of this and 
other genetic markers may eventually make it possible to pinpoint 
what occurs in individual patients, improve diagnostic procedures, 
and customize patients’ treatment plans.
The Sun Sheds Light on Multiple Sclerosis
The risk for developing multiple sclerosis is strongly associated 
with latitude; living farther from the equator increases the risk. Even 
people of shared ancestry may differ in susceptibility if they live at 
different latitudes, especially when they are young. Recent research 
points to the sun as the reason for this effect.
A study published in Neurology examined the effect of childhood 
sun exposure in pairs of identical twins in North America.6 The study, 
led by Thomas Mack of the Keck School of Medicine at the University 
of Southern California, showed that, within pairs of twins, the one 
who spent more time outdoors as a child (going to the beach, or 
playing team sports, for example) had a lower risk of multiple sclero-
sis. By studying genetically identical twins, the investigators were able 
to demonstrate the association of environmental factors without the 
confounding effects of genetic differences.
Another study, conducted in Norway and published in the Journal 
of Neurology, showed that childhood sun exposure reduced risk of 
multiple sclerosis.7 The study also showed that a diet rich in fish 
reduced risk. The authors, led by Margitta Kampman, suggested 
that the high vitamin D content of fish might be responsible for its 
protective effect.
Evidence has indicated a direct effect of vitamin D on the brain. 
Studies have demonstrated that vitamin D reduces stroke risk in 
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animal models. The protective effect of sun exposure could come 
from a direct effect of exposure to ultraviolet radiation or, indirectly, 
through the production of vitamin D. We obtain some vitamin D from 
food, but the majority is produced by the skin through exposure to 
the sun, which is why vitamin D is sometimes called the sunshine 
vitamin. In winter, when the days are shorter and the sun is lower in 
the sky, vitamin D deficiencies are common. In fact, people living in 
latitudes even with or north of Boston obtain no vitamin D at all from 
the sun between November and February.
Vitamin D is known to be important for maintaining bone density. 
Perhaps less well known are the regulatory effects of vitamin D on the 
immune system. Receptors for vitamin D are present on cells of the 
immune system, and vitamin D deficiency has been associated with 
autoimmune or inflammatory diseases, including asthma, rheumatoid 
arthritis, inflammatory bowel disease, and diabetes. Scientists also 
are exploring the protective role of vitamin D in mouse models of 
multiple sclerosis.
Several recent population studies have shown that vitamin D levels 
in the blood correlate inversely with the risk of being diagnosed with 
multiple sclerosis. A study conducted in Tasmania, Australia, showed 
that people with the disease had lower blood levels of vitamin D.8 A 
study of U.S. military personnel, published December 20, 2006, in 
the Journal of the American Medical Association, measured vitamin 
D levels over time and found that decreased levels preceded onset of 
multiple sclerosis symptoms.
This finding supports the interpretation that vitamin D deficiency 
is a contributing factor to multiple sclerosis, rather than a result of 
Research in 2007 indicates 
that vitamin D, produced in 
the skin through exposure to 
the sun, may reduce the risk 
of multiple sclerosis.
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reduced sun exposure due to disability.9 Yet another study, this one 
from Finland and published in the Journal of Neurology, Neurosurgery, 
and Psychiatry showed that decreased levels of vitamin D in the blood 
were associated with worsening of symptoms.10
Because of its potential effects on susceptibility to multiple sclero-
sis and other diseases, investigators are taking a new look at recom-
mendations for dietary intake of vitamin D. Currently, the Institute 
of Medicine of the National Academy of Sciences considers 200 
International Units (IU), or 5 micrograms, of vitamin D per day to be 
adequate for most people aged 50 and under. In September 2007, the 
Canadian Paediatric Society issued a statement recommending that 
pregnant and nursing women consider vitamin D supplementation up 
to 2,000 IU per day.11
The group also recommended that babies that are exclusively 
breastfed get 400 IU of vitamin D and that babies living above 50 
degrees latitude (from about as far north as Edmonton, Alberta) 
receive 800 IU in the winter months. Animal studies suggest that 
vitamin D can be used to both prevent and treat multiple sclerosis, 
but more research is needed before these findings can be applied 
to humans.
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Pain is the number one reason people seek medical care in the United States. Yet physicians continue to struggle to find effective means of treating and managing both chronic and 
acute pain.
Pain researchers took several approaches in 2007. Some sought 
ways to reduce addiction to powerful opioid drugs, which are often 
the most effective means of providing pain relief. Others identified a 
crucial pain-signaling pathway that opens new avenues of treatment 
for patients suffering from significant “phantom” pain following a 
spinal cord injury. Still others found a more effective treatment for 
chronic neuropathic pain, offering hope to millions of people who 
suffer from disabling back pain.
Chronic Pain and Opioid Addiction
For several thousand years, opium has been used to relieve pain 
and suffering, and many drugs derived from opium, called opioid 
drugs, are used today for both legitimate and illegitimate purposes. 
The tendency of these drugs to cause addiction because of their 
powerful euphoric effect has created a conflict for physicians, who 
must balance the patient’s need for pain relief against the risk of 
causing dependency.
Although chronic pain diminishes the analgesic effect of many 
opioid drugs, researchers at Wake Forest University School of 
Medicine have found that it also weakens an individual’s tendency 
to become addicted to some of these drugs, including morphine, 
hydromorphone, and fentanyl. The findings, which appeared in the 
February 27, 2007, issue of Anesthesiology, suggest that if chronic pain 
is not treated adequately with appropriate drugs, patients eventually 
will stop taking prescribed drugs and seek alternatives, including 
heroin and methadone, that are more effective at treating chronic pain 
but that have the feared addictive consequences.1
The Wake Forest researchers implanted catheters in rats, half of 
which had their spinal nerves ligated, or twisted, and then trained 
them to self-administer clonidine and adenosine, two opioid drugs 
that effectively reverse hypersensitivity to pain. The researchers found 
that neither drug had any effect on heroin-seeking behavior in normal 
rats, because, they say, sites in the brain and not the spinal cord 
mediate the abuse potential of heroin in a normal animal.
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In rats with chronic pain, however, the researchers found that 
administering clonidine into the spine drastically reduced heroin-
seeking behaviors. The administration of adenosine at the spinal level 
did not affect heroin-seeking in the injured rats, even though this drug 
is known to alleviate hypersensitivity to pain after nerve injury. These 
findings suggest, at least in the animal model, that both clonidine and 
adenosine given together can produce pain relief without producing 
the urge to use heroin.
Another study revealed that a subgroup of chronic pain patients is 
prone to addictive drug-seeking behavior. Researchers at Massachusetts 
General Hospital examined several studies to determine how opioid 
addiction relates to chronic pain relief. The researchers reported in 
the journal Pain in June that early assumptions that addiction would 
be rare among patients treated for chronic pain were incorrect.2 
Rather, drug-seeking and other negative behaviors do occur in a small 
group of chronic pain patients. How addiction starts, however, is 
different for this subgroup. Specifically, in this subgroup, the transi-
tion to addiction is subtler and more difficult to identify.
Although physicians are armed with a wealth of information that 
can help prevent opioid addiction when treating patients with chronic 
pain, the researchers say better tools are needed to help determine 
who among these patients is likely to become addicted. Physicians, 
they add, can then develop structured treatment regimens with 
support from addiction specialists, which may require using alterna-
tives to opioid drugs.
Pain Signal Targeting
Nearly 80 percent of people who suffer a spinal cord injury develop 
clinically significant pain, describing it as burning, aching, shooting, 
or stabbing. In addition, many patients who have lost feeling in some 
parts of their bodies suffer from phantom pain in which they “feel” 
the body below the spinal cord lesion and experience pain in these 
areas of total sensory loss.
A dysfunction of the nervous system causes the abnormal pain that 
A subgroup of chronic pain patients is prone to addictive  
drug-seeking behavior.
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often develops following spinal cord injury, say scientists at the Yale 
University Center for Neuroscience and Regeneration Research. The 
researchers reported in the February 28, 2007, issue of the Journal of 
Neuroscience that they had demonstrated for the first time a direct 
signaling pathway in the injured spinal cord between neurons and 
microglia, immune cells that reside in the central nervous system and 
mount an inflammatory response to protect the nervous system, but 
at times may actually damage it.3
Using adult rats that underwent spinal cord contusion injury, the 
researchers found that a molecule called prostaglandin E2 (PGE2) is 
central in microglia-mediated chronic pain. This molecule is released 
by activated microglia and contributes to the sensitization of spinal 
neurons after injury.
Targeting this microglia-neuron signaling mechanism, the Yale 
researchers say, may lead to successful pain management following 
spinal cord injury. The researchers are examining compounds that 
block the signaling pathway at several sites in the spinal cord. The 
prototype compound is minocycline, an antibiotic approved by the 
Food and Drug Administration to treat a number of infections, which 
is also in clinical trials to test its effectiveness in currently “off-label” 
uses to treat several neurological disorders, such as Huntington’s 
disease, amyotrophic lateral sclerosis, and multiple sclerosis.
The Yale team is using a type of imaging called positron emission 
tomography to attempt to verify evidence that a similar, if not identi-
cal, pain mechanism exists in both humans and mice. If so, they will 
test the effectiveness of minocycline in patients with spinal cord injury 
in shutting down the PGE2 pain signaling mechanism.
Microglial cells, seen here as 
bright spots among darker 
neurons in the lumbar dorsal 
horn, are part of what cause 
chronic pain after a spinal 
cord injury.
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Effective Back Pain Relief with Neurostimulation
Back pain is one of the most common medical problems in the 
United States, affecting about 80 percent of the population at some 
point in their lives. According to a Duke University study in 2004, 
back pain—in the form of lower back pain, neck pain, or sciatica—
costs the United States nearly $100 billion per year in medical bills, 
disability payments, and lost productivity. Although conventional 
therapies and surgery have proved somewhat effective at reducing 
back pain, researchers have found that neurostimulation, a treatment 
that employs an implantable medical device to deliver electrical 
impulses, is better at relieving chronic neuropathic pain in the back 
and legs. These electrical impulses are sent to the epidural space in the 
spinal column in order to keep pain signals from reaching the brain.
In the largest multi-center, randomized, controlled trial of neuro-
stimulation to date, an international consortium of researchers, led 
by Krishna Kumar of Regina General Hospital in Canada, found 
that neurostimulation provides better pain relief, quality of life and 
functional capacity than conventional treatments, such as pain drugs, 
pharmaceutical nerve blocks, steroid injections, physical therapy, and 
chiropractic care.
The study, published in Pain in November, found that six months 
after treatment, nearly half the patients who received neurostimula-
tion along with conventional treatments experienced an improvement 
in leg pain at least 50 percent greater than the improvement reported 
by people who received only conventional therapy.4 Each of the 
patients had undergone at least one back surgery for a herniated disk 
but continued to experience moderate to severe pain in one or both 
legs and in the back at least six months after their surgery.
Because disabling neuropathic pain is difficult to treat, the 
researchers say neurostimulation should be added to the list of treat-
ments routinely offered to patients who suffer chronic back pain.
On the West Coast, physicians at Coast Pain Management in 
California reported in the July Neuromodulation that a specific type 
of neurostimulation called peripheral nerve field stimulation is a safe 
and effective alternative for patients with chronic low back pain.5 The 
physician-scientists examined the effectiveness of this treatment in six 
patients with chronic low back pain with whom conventional thera-
pies were unsuccessful. In contrast to spinal cord or direct peripheral 
nerve stimulation, peripheral nerve field stimulation uses leads placed 
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through the skin and into the area of pain to stimulate the region of 
the affected nerves. In each of the six patients, they reported, periph-
eral nerve field stimulation allowed a reduction in pain medication 
and an increase in activity level, along with higher quality of life.
Peripheral nerve field stimulation has distinct advantages over 
other forms of neurostimulation, including fewer complications 
and lower morbidity, according to the researchers, who say that this 
treatment shows promise as a complement to existing therapies and 
deserves further study.
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Mental health research in 2007 focused on gaining further understanding of the origins of certain disorders and on finding effective treatments. Many scientists maintained an 
emphasis on the underlying role of genetics in psychiatric disorders 
but moved toward more targeted study of what role genes play in 
management and treatment. In addition, neurobiological studies have 
broadened in scope by examining neural circuits, or connections 
between distinct parts of the brain, instead of individual regions, to 
understand how interrupted or misplaced signals may affect men-
tal health.
Recent findings in depression research have led to better under-
standing of neural circuitry problems that may underlie the disorder, 
as well as potential non-drug treatments to alleviate these problems. 
Research into bipolar disorder has yielded a probable genetic indi-
cator as well as the disorder’s first mouse model for further study. 
Finally, studies looking at both schizophrenia and alcoholism have 
identified new prospective drug treatments.
Depression
The hippocampus, integrally related to the system responsible for 
human emotion—the limbic system—has long been associated with 
memory and spatial processing. On the heels of findings that the 
hippocampus projects to brain areas implicated in depression and 
that antidepressant-stimulated hippocampal neurogenesis is associ-
ated with positive behavioral responses to the drugs, this region also 
has become an area of interest in the study of depression.
In a Science report published August 10, Karl Deisseroth and 
interdisciplinary colleagues at Stanford University identified a neuro-
physiological circuit connecting the hippocampus, including the 
dentate gyrus, to depression.1 This circuit may be of interest for 
future interventions.
The researchers subjected one group of rats to stressful situations, 
such as sleep deprivation, hostile lighting, and loud noises, while a 
control group lived in a relatively stress-free environment. In addi-
tion, some of the stressed rats were given antidepressant medication.
After several weeks, both groups of rats were observed after 
being submerged in water. The stressed rats that were not given 
anti-depressants swam less vigorously than the non-stressed and 
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the medicated rats, which the researchers say represents a feeling of 
hopelessness.
The scientists then used a high-speed imaging technique called 
voltage-sensitive dye imaging to measure the electrical activity in the 
rats’ hippocampal area, in particular as it projected to the dentate 
gyrus. They found that the signals successfully conducted across the 
circuit in the non-stressed and medicated rats but were interrupted in 
the stressed ones, eventually leading activity in the circuit to die out.
These findings suggest that there may be no single cause for 
depression but that a single life event, such as a family member’s death 
or a stressful work situation, might cause a problem in the circuit, 
leading to the pervasive symptoms of depression. The authors also 
suggest the circuit as a prospective site for treatment therapies.
Other neural circuits in the limbic system have been associ-
ated with depression. These circuits often include brain areas 
such as the prefrontal cortex, amygdale, and subgenual cingulate 
cortex—areas associated with emotional processing, production of 
the neurotransmitters involved in sad emotions, and response to 
antidepressant drugs.
In a September Nature Neuroscience review by Kerry J. Ressler and 
Helen S. Mayberg of Emory University’s Department of Psychiatry 
and Behavioral Sciences, the authors argue that progress made in 
identifying and understanding the actions of depression-associated 
neural circuits, and in pinpointing specific areas within these circuits 
where their dysregulation is associated with behavioral symptoms, 
now makes the use of promising non-drug therapies feasible.2 Finding 
effective alternatives to currently available antidepressant medications 
is critically important for people with intractable depression who do 
not respond to these medications.
Researcher Karl Deisseroth 
and colleagues at 
Stanford University used 
a high-speed imaging 
technique called voltage-
sensitive dye imaging 
to link a faulty circuit 
in the hippocampus to 
depression in rats.
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Foremost among these non-drug approaches is deep brain stimula-
tion (see also Movement Disorders, page 27, and Neuroethics, page 
43). Clinical studies of deep brain stimulation for treating intractable 
depression were based on Mayberg’s initial imaging studies, using 
positron emission tomography, that identified the subgenual cingulate 
cortex (Cg25) as an area associated with severe depression. Deep brain 
stimulation alters communication within and among brain circuits in 
this region via high-frequency stimulation to implanted electrodes.
The treatment was associated with antidepressant effects, a 
marked reduction in cerebral blood flow to area Cg25, and changes in 
multiple brain regions implicated in mood regulation and treatment 
response. Further clinical studies are under way in a larger number 
Earlier imaging studies associated too much activity in area Cg25, part of the 
subgenual cingulate cortex, with severe depression. Work in 2007 suggests 
that deep brain stimulation in area Cg25 has an antidepressant effect. 
These images show a reduction in blood flow to area Cg25 after deep brain 
stimulation, which involves the stimulation of an implanted electrode.
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of patients to further establish the treatment’s safety and efficacy, to 
determine how brain circuitry in this region is involved in depression, 
and to determine how deep brain stimulation effectively intervenes in 
this circuitry.
Other potential alternatives to antidepressant medications include 
vagus nerve stimulation, electroconvulsive therapy, and repetitive 
transcranial magnetic stimulation. While electroconvulsive therapy 
has long been used to treat intractible depression and has regained 
acceptance in recent years, deep brain stimulation, vagus nerve 
stimulation, and transcranial magnetic stimulation all are being tested 
to determine their ability to interrupt and modify brain circuits that 
have been linked to depression and emotion regulation.
By using neuroimaging techniques such as positron emission 
tomography and functional magnetic resonance imaging before and 
after treatment, scientists are able to see changes in regional activation 
in the brain, showing the changes to the circuits involved. Improved 
understanding of the underlying neural circuitry may also make these 
therapies viable candidates to treat other psychiatric disorders, such 
as obsessive-compulsive disorder.
Although deep brain stimulation is now an accepted treatment 
for Parkinson’s disease patients who are no longer able to tolerate 
drug treatment with L-DOPA and shows promise in treating intrac-
table depression, Ressler and Mayberg suggest that more research 
is needed, not only to better understand the long-term effects to 
patients but also to define optimal treatment conditions.
Bipolar Disorder
Previous studies have suggested that problems with the regulation 
of circadian rhythms, or the body’s internal clock, may play a pivotal 
role in bipolar disorder, a psychiatric condition sometimes also 
referred to as manic depression. In a study published in Proceedings 
of the National Academy of Sciences USA, Colleen McClung and 
colleagues created the first mutant mouse model of bipolar disorder 
by disrupting a gene called clock (circadian locomotor output cycles 
kaput) by inducing mutations to proteins that regulate the animal’s 
circadian rhythms.3
Clock is believed to produce a protein necessary to regulate the 
complex feedback loop governing circadian rhythms in the brain. 
McClung’s mutant, clock-free mice showed mania-type behaviors that 
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mimic human bipolar symptoms. Those symptoms included hyperac-
tivity and reduced sleep time as well as heightened response to novel 
stimuli and stimulants such as cocaine.
The clock mutant mouse is the first animal model of mania to 
be created, offering the potential for greater understanding of how 
circadian rhythms are neurally and genetically regulated and how 
dysregulation may lead to bipolar symptoms. Furthermore, the model 
presents researchers with a new direction in which to develop new 
and improved treatment options for bipolar patients.
Obsessive-Compulsive Disorder
In the past few years, research into obsessive-compulsive disorder 
(OCD) has consistently implicated the striatum, the input center of the 
basal ganglia system. Malfunctions in this system have been implicated 
in dysfunction of motor control, learning, and reward processing.
Guoping Feng and colleagues studied the role of a gene that is 
prevalent in the striatum. In a paper published in Nature, Feng’s team 
used gene knockout techniques to remove from mice the sapap3 gene, 
which is critical for the effective synaptic communication of neurons 
in the brain that use the neurotransmitter glutamate.4
The sapap3 mutant mice showed several OCD-like symptoms, 
including increased anxiety and excessive personal grooming to the 
point of hair loss. However, when the mice were treated with fluox-
etine (Prozac), a drug commonly used to treat OCD, or when the 
sapap3 gene was directly reinserted into the striatum of the mutated 
mice, the symptoms abated.
These findings provide new insight into both the underly-
ing neurobiological causes of obsessive-compulsive disorder and 
avenues for future treatment. Previous studies and treatments 
focused on the neurotransmitter serotonin, so this result, implicat-
ing glutamate, may inspire work on new drug therapies that target 
glutamate neurotransmission.
Previous studies and treatments focused on the neurotransmitter 
serotonin, so this result, implicating glutamate, may inspire work 
on new drug therapies that target glutamate neurotransmission.
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Schizophrenia
In 2005 and 2006, a group of independent studies showed that 
atypical, or second-generation, anti-psychotic medications were less 
effective than older drugs that often cause more side effects. In one 
study, led by Jeffrey Lieberman and published in 2005 in the New 
England Journal of Medicine, the exception was olanzapine, an atypi-
cal drug with which patients discontinued use at a lower rate than 
with its peers.5 However, patients experienced persistent weight gain 
and other metabolic side effects. The results of these studies caused 
widespread concern among psychiatrists and researchers about treat-
ment options for schizophrenic patients.
Another group of researchers, led by Sandeep Patil of Lilly 
Research Laboratories, tested a new drug called LY2140023, which 
moderates the neurotransmitter glutamate in the brain. In a paper in 
the September Nature Medicine, the researchers compared the new 
drug with olanzapine and a placebo for four weeks in 200 patients 
with schizophrenia.6
The group found that more than 25 percent of patients who took 
LY2140023 responded positively to treatment, without negative side 
effects. The results suggest that drugs that help the brain adapt to 
disrupted glutamate pathways may be a safe and useful treatment 
option in the future for those suffering from schizophrenia.
Alcoholism
Drugs have been used with mixed success in the treatment of 
alcoholism. A study by Lara Ray and Kent Hutchison that appeared in 
September in the Archives of General Psychiatry suggests that naltrex-
one, an opioid receptor antagonist and one of the drugs prescribed to 
combat alcoholism, is more successful in the treatment of individuals 
with a certain genotype than others.7
Ray and Hutchison found that people addicted to alcohol who 
had a certain type of a gene called OPRM1 not only reported greater 
feelings of intoxication after drinking but also had a reduced response 
to alcohol after taking naltrexone. These results provide an avenue for 
further study not only of genetic indicators in alcoholism but also of 
how those indicators may interact with treatment.
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Future Directions in Study and Treatment
The completion of the International HapMap Project, a catalog of 
common human genetic variants, in 2005 has provided mental health 
researchers with a new opportunity to undertake whole-genome studies 
to identify genetic factors underlying complex psychiatric disorders. 
“Genome-wide association” studies in heart disease, diabetes, and 
certain cancers have yielded extensive new avenues for the discovery 
of disease development and treatment, and scientists are hopeful that 
comparable studies examining schizophrenia, bipolar disorder, and 
obsessive-compulsive disorder will yield similar success.
Thomas R. Insel, director of the National Institute of Mental 
Health, and Thomas Lehner of the institute’s Division of Neuroscience 
and Basic Behavioral Science argue in a May editorial in Biological 
Psychiatry that the potential for genome-wide association is high 
but that researchers need to consider the requirements to success-
fully carry out these analyses.8 Large sample sizes with well-defined 
characteristics are a must, which may be difficult for smaller research 
laboratories with a small pool of patients. Also, disorders with broad 
or contentious diagnostic criteria may present difficulties in narrow-
ing down the genetic factors involved.
To combat these issues, the authors advocate the sharing of 
genomic databases. One such database is the NIMH’s bipolar 
disorder phenome database. Researchers at the institute compiled 
a database of validated variables for more than 5,000 people with 
bipolar disorder.9
The database is available to laboratories and research centers 
to identify genetic indicators and effects. As more such databases 
are assembled and made available for public use, a more sophisti-
cated understanding of the role of genes in psychiatric disorders, 
as well as opportunities for new and more effective treatments, may 
be possible.
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In 2007, scientists continued to explore the ways in which the brain processes and responds to perceived stimulation. Researchers at Harvard University investigated the mechanism by which we feel 
sick and took the first steps toward reducing those sensations for 
patients with certain conditions. Researchers at both Duke and Johns 
Hopkins universities made progress in the complicated investigation 
of sound perception, studying music and speech, respectively.
The Fever Response
A person who feels as though he or she is getting sick typically 
experiences a familiar set of symptoms: body aches, fatigue, poor 
appetite, and the chills and hot flashes associated with a fever. The 
body develops a fever in response to several situations perceived as 
threats. Bacterial infections are the most common fever-producing 
events, but some viral infections, along with noninfectious diseases 
involving the immune system, such as rheumatoid arthritis and 
Crohn’s disease, will also prompt the body to elevate its temperature 
above 98.6 degrees Fahrenheit.
Although running a fever is an unpleasant experience, fevers aid 
the body in its fight against infection. White blood cells, which are 
part of the body’s immune system, become more active when the 
body’s temperature elevates, mounting a stronger defense against 
the invading organisms.1 Infectious agents also have a more difficult 
time surviving and flourishing in a system that is getting hotter. Until 
recently, however, scientists did not fully understand the mechanism 
by which fevers are produced.
Scientists knew that a fever occurs when prostaglandin E2 (PGE2), 
a hormone made by blood vessels on the edge of the brain, is released 
into the blood, crosses into the brain, and binds to EP3 prostaglandin 
receptors (EP3Rs). These receptors are located in the part of the 
hypothalamus called the median preoptic nucleus as well as in other 
parts of the central nervous system.
The question that Clifford B. Saper and his research team at 
Harvard sought to answer in 2007 was this: which receptors respond 
to the PGE2 hormone by triggering the body to run a fever?
Saper’s team investigated receptor response via a viral vector—a 
benign virus modified to deliver specific genetic material—called 
adeno-associated virus. In this case, adeno-associated virus selectively 
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“chopped out” the EP3 gene, thereby preventing any PGE2 hormone 
from binding at that site. The team incapacitated receptors in the 
brains of mice, working with one specific, tiny area at a time, and then 
tested the animals’ fever response.
When the EP3R located in the median preoptic nucleus were 
incapacitated—when the EP3 genes there were “chopped out”—the 
mice did not develop fevers in response to infection.2
Saper’s team suspects that the PGE2 hormone and its EP3R are 
responsible for the range of familiar symptoms one feels when one 
feels sick, because drugs such as aspirin and ibuprofen, which block 
the synthesis of prostaglandins, reduce both fever and pain. They 
decided to begin by investigating the fever response for two reasons. 
First, it is relatively easy to measure body temperature (easier than 
measuring aches or fatigue). Second, the research on fever was further 
along than research on the other responses to infection. In 2008, 
Saper and his colleagues will again use mice to explore the role that 
the PGE2 hormone and its EP3RS play in generating the pain response 
to illness.
If the mechanism by which the body experiences pain when it is 
sick can be deciphered as exactly as the mechanism by which it runs a 
fever, pain could then be controlled by managing the PGE2 hormone 
and its receptors. This progression would potentially provide clini-
cians with an alternative to narcotics and other pain management 
remedies when they are treating the discomfort of patients with 
chronic or terminal diseases—situations in which the pain response is 
Researchers were 
able to prevent the 
development of fevers 
in mice by blocking EP3 
prostaglandin receptors 
(stained white) above 
the third ventricle, a 
normal opening in the 
brain. The dark cells 
have been affected by 
the injection of a gene 
that blocks EP3 receptors. 
The inset shows a 
higher magnification of 
this process.
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no longer prophylactic and adaptive. Ideally, physicians could simply 
“dial down” the pain response in these patients to increase their 
quality of life.
The Universal Human Appreciation of Music
The human ear can hear a wide variety of tones, but musicolo-
gists who study music across different cultures have determined that 
people use approximately the same small subset of tones called scales 
in the creation of music. Dale Purves and his research team at Duke 
wondered why, and they hypothesized that it had something to do 
with the tones present in human speech. In 2007, these researchers set 
out to decode the connection between human speech and the musical 
tones that all humans find agreeable.
Initially, the team thought the preferred intervals in music mimicked 
the rise and fall of pitch when humans speak. They expected to be 
able to map common voice modulation over commonly used scales, 
but the intervals were not the same. The team then turned to what are 
called formants.
When an instrument produces a note, that note can be represented 
as a spectrum. Formants are the most important frequency compo-
nents represented when an instrument, including the human voice 
box, generates a note. When a person speaks a vowel sound, it is those 
strongest pitches, or formants, that make the sound distinguishable 
from other vowel sounds.
Purves and his colleagues statistically analyzed spectra created by 
music and spoken vowels (the spectra were represented visually) and 
discovered that 68 percent of the time, the same intervals that create 
the music deemed pleasing by humans across time and geography 
were also emphasized when people spoke vowel sounds.3 The empha-
sized harmonics in human speech—the frequencies that harmonize 
and form what we recognize as a person speaking a vowel sound—are 
often the same as our chromatic musical intervals. In other words, the 
tones of music are actually embedded in our speech.
The principles of evolutionary weeding suggest that humans’ 
aesthetic taste is rooted in something practical. This discovery 
suggests that the harmonies the brain finds pleasing identify aspects of 
our environment that bear important information, or did at one time. 
Paying attention to another person speaking used to spell the differ-
ence between life and death (it still can); those who found speech 
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most pleasant listened, reaped its lifesaving benefits, and went on to 
reproduce. The descendants of those early humans eventually used 
those same lovely intervals to create music, this theory suggests.
Exploring music in this way has piqued Purves’s interest, and 
he plans to investigate the link between music and emotions next. 
Humans interpret music played in a major scale as bright and hopeful, 
while a tune in a minor scale seems melancholic. Purves speculates 
that changes in the larynx, which occur in response to activity in the 
nervous system, cause formant changes when we speak that reflect 
these major and minor scales. According to this theory, a happy person’s 
nervous system cues the larynx to produce major-scale formants; a sad 
person’s nervous system results in minor-scale formants.
The Complex Perception of Spoken Language
In the 1970s, Murray Sachs and Eric D. Young of Johns Hopkins 
University discovered the mechanism whereby the brain codes, and 
therefore understands, speech. They discovered that hair cells in 
the ear vibrate in response to sound, and that this vibration is trans-
lated into an electrical signal—a nerve spike—that the auditory nerve 
conducts to other parts of the brain.
In the 1980s, they shed light on how the brain represents the 
variety of information that is carried in through the ears. Each of 
the 30,000 auditory nerve fibers represents a very small number of 
specific frequencies. The dominant frequencies, or formants—the 
same patterns examined by Purves’s team—are then extracted in the 
The intervals between notes in the 
chromatic musical scale (the marked 
piano keys) correspond to key 
human speech tones (the crests of 
the white line). These peaks allow us 
to recognize vowel sounds and may 
help explain why humans appreciate 
certain tones as musical.
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cochlear nucleus, which interprets auditory nerve fibers’ responses 
to frequency.
Xiaoqin Wang, who has since joined the research group, is inter-
ested in how the brain processes speech-like stimuli in the auditory 
cortex. He began by using marmoset monkeys to study how animals 
determine which auditory stimuli are worth their attention. Marmosets 
were selected for the range of their vocal repertoire; they chirp to 
convey many kinds of social and practical information. They also 
continue to chirp in meaningful ways in captivity. Wang and his team 
played recorded monkey calls forward (as they are normally heard) 
and then backward, and determined that monkeys and cats process 
monkey calls differently. The cats’ response to the monkey calls did 
not change based on how the calls were played, but the neurons in the 
same-species monkeys responded more strongly to the forward, famil-
iar version of the call. Thus it was determined that animals process the 
sounds of their own species uniquely, and those differences showed 
up in a part of the brain called the inferior colliculus.
The inferior colliculus, which Young has studied extensively, 
introduces time as a factor in understanding speech. When we listen 
to speech, we hear, decipher, and store individual sounds in our 
short-term memory, and we anticipate the next sounds. When we 
listen to multiple speakers simultaneously, as in a group discussion, 
those streams are understood separately and kept distinct. The speed 
at which the brain can make sense of speech is what allows it to be a 
practical way for humans to convey information.
Currently, Young is investigating how the auditory system uses 
short-term memory along with moment-to-moment processing of 
sound to make sense of language. The next step in his inquiry will be 
to study the mechanisms by which we are able to anticipate what a 
person will say next.
Sachs plans to rejoin Young and Wang in the lab in 2008 to begin 
studying how one marmoset monkey distinguishes the calls of another 
specific monkey when many, both seen and unseen, are chirping 
away. This isolation of all the sounds from one source is referred to as 
forming an auditory object. The researchers are looking for neurons 
in the inferior colliculus that do this analysis, the same sort of analysis 
that allows humans to make sense of speech in a crowd or identify the 
sound of a particular instrument in a band or orchestra.
The group also plans to study the process of perceiving music. 
Like Purves, Sachs is interested in how sound affects emotions.
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The immature, versatile precursors to human tissue known as stem cells continue to show promise in understanding and treating disease—particularly neurodegenerative diseases, in 
which crucial populations of brain cells begin to die. In 2007, 
researchers reported new ways of obtaining stem cells in quantity, 
without engendering ethical concerns, for use throughout the body, 
including the brain. Additionally, studies have revealed how stem cells 
can help to unravel processes of neural degeneration and be used 
effectively to deliver therapies to dying brain cells.
Stem Cells from Skin Tissue
In 2007, stem cell research took a giant step closer to a long-
desired goal: coaxing cells from adult human tissue to behave like 
embryonic stem cells, thus sidestepping the ethical hurdles posed by 
the use of embryos. In the November 20 Cell, Shinya Yamanaka and 
colleagues at Kyoto University, Japan, inserted four genes that are 
active during embryonic development into a modified virus. The virus 
was then inserted into fibroblasts, which are skin cells taken from 
adults. These genes then “reprogrammed” the skin cells to produce 
a line of stem cells that could self-renew and produce as many new 
cells as embryonic stem cells ordinarily produce.1 Another team, led 
by James Thompson of the University of Wisconsin, Madison, used 
a slightly different combination of genes to similarly reprogram skin 
cells taken from newborns. Their results appeared online November 
19 and in print December 21 in Science.2
Stem cells produced through this method have the same “pluri-
potency” of embryonic stem cells, meaning they can develop into 
any desired type of tissue. Two studies in the July 19 Nature, one by 
Yamanaka and one by Rudolph Jaenisch of the Whitehead Institute, 
Boston, and colleagues, demonstrated this pluripotency in cell lines 
produced from mouse skin cells using the same basic technique.3, 4
The most immediate use of this technique will be to produce cell 
lines that contain genes known to produce specific diseases, such 
as the inherited forms of Alzheimer’s or Parkinson’s disease. These 
cell lines can be used to investigate how the gene products produce 
neurodegeneration and to screen potential therapies. Ultimately this 
new stem cell technique is expected to usher in a new age of medicine 
in which many brain diseases can be treated by replacing damaged 
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nerve cells with a new population of brain cells derived from the 
patient’s own skin cells. But many hurdles remain. For example, use 
of modified viruses to deliver genes into skin cells may lead to devel-
opment of tumors. Additionally, the stem cells derived from skin cells 
are not identical to those produced by embryos, and the differences 
may prove significant. While these potential problems will need to be 
successfully addressed, the ability to produce stem cells in quantity 
without involving fertilized human embryos is a major step forward.
Stem Cells from Non-Viable Embryos
The successful cloning of Dolly the sheep in 1997, by a process 
known as somatic cell nuclear transfer, raised hopes that the same 
approach could produce an endless supply of stem cells—either healthy 
cells from the patient or, for research purposes, cells with a particular 
genetic disorder. The process, however, involves inserting the desired 
genetic material into an oocyte, or egg cell. Obtaining egg cells from 
humans in sufficient numbers poses technical and ethical hurdles.
A study in the June 7 Nature shows a way around many of these 
hurdles. Working with mice, Dieter Egli and colleagues at Harvard 
University showed that it is possible to introduce stem-cell material 
into fertilized embryos, or zygotes—something that previous research 
had failed to accomplish.
In one phase of the experiment the researchers took zygotes with 
extra chromosomes—which are non-viable and thus cannot develop 
into living offspring—removed the abnormal chromosomes, and 
inserted the DNA of the stem cells they wanted to propagate. An 
estimated 3 to 5 percent of the human zygotes in in vitro fertilization 
clinics carry such abnormalities and are usually discarded, according 
to a 2000 report of the American Society for Reproductive Medicine/
Society for Assisted Reproductive Technology Registry.5 The study 
shows for the first time how these unusable zygotes—numbering in 
the tens of thousands—could generate a vast supply of stem cells.
This approach would not destroy a potential life, since the 
embryos’ chromosomal abnormalities are incompatible with life. In 
addition, the genetic material in the resulting stem cells would not be 
that of the original donors. The technique could provide an ethically 
acceptable way of generating stem cells in quantity for use in research-
ing many human genetic disorders.6
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Not All Neural Stem Cells Are Alike
In seeking to harness the therapeutic power of neural stem cells, 
researchers need a thorough understanding of the factors that control 
their development. A common assumption is that neural stem cells 
begin life in a uniform state of potential and can theoretically be 
nudged onto almost any developmental path.
However, this assumption is based on studies of cultured cells; less 
is known about how stem cells behave in the brain. A study in the 
July 20 Science shows that a stem cell’s fate is restricted depending on 
its location.7
Working with newborn and adult mice, Arturo Alvarez-Buylla of 
the University of California at San Francisco and colleagues tracked 
the progeny of small groups of stem cells. Stem cells were selectively, 
and permanently, labeled with green fluorescent protein. The team 
followed the fate of stem cells from 15 different locations of a large 
“germinal” brain region in the adult, where neurons and other brain 
cells continue to be born after birth.
Mature, green-labeled nerve cells were formed from all sites, 
but the types of neurons produced differed depending on the site 
of origin. In addition, the stem cells proved remarkably resistant to 
a change in environment. Even when removed from the brain and 
grown in culture, exposed to a variety of growth factors—or when 
grafted into different sites in the germinal regions of other animals—
the stem cells gave rise to neurons and other brain cells, but the 
neurons produced were once again specific to their original location. 
The finding suggests that although stem cells are indeed versatile, the 
types of neurons an individual stem cell can generate may be speci-
fied for one part of the brain and not readily able to assume a new 
identity if transplanted to a different location. This region specificity 
might restrict the therapeutic usefulness of a given population of 
stem cells.
Stem Cells Protect Neurons in ALS
Stem cells are usually hailed for their potential to produce future 
generations of healthy replacements for cells that die in degenerative 
disease. But they can also be used to deliver therapeutic substances 
to ailing neurons.
Working with a line of embryonic stem cells, Clive Svendsen of the 
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University of Wisconsin, Madison, and colleagues engineered stem 
cells to secrete a compound called glial-derived neurotrophic factor 
(GDNF), which nourishes and protects neurons. Reporting in the July 
31 edition of PLoS One, the online journal of the Public Library of 
Science, the investigators implanted GDNF-secreting stem cells into 
the spinal cords of rats with amyotrophic lateral sclerosis (ALS, or 
Lou Gehrig’s disease), which attacks motor neurons.8
The transplants took hold and, in rats with early-stage disease, 
protected virtually all of the injured neurons. The engineered cells 
also showed a high affinity for damaged neurons, moving directly to 
the injured areas and pumping out GDNF.
The procedure did not restore communication between motor 
neurons and muscles or improve the rats’ ability to use their limbs; as 
a treatment for ALS its role would be limited to keeping the neurons 
alive. However, the approach demonstrates a lesser-known use for 
stem cells that could be useful in treating a variety of disorders. 
This approach of using stem cells to travel to sites of damage in the 
brain is also being investigated for delivering targeted treatment to 
brain tumors.
Powerful New Tools to Study Disease
Two teams of researchers studying amyotrophic lateral sclerosis 
have used stem cells to provide a vital clue to this mysterious disease. 
More than 90 percent of cases are sporadic, meaning that the patient 
has no family history of the disease. However, a mutated gene that 
encodes an enzyme called superoxide dismutase-1 (SOD1) has been 
identified as a cause of the disease in a few people.
Clive Svendsen of the 
University of Wisconsin, 
Madison, and colleagues 
have developed stem cells 
that secrete a neuron-
protecting compound 
called glial-derived 
neurotrophic factor, or 
GDNF. Implants of these 
cells kept damaged motor 
neurons alive in rats with 
early-stage ALS.
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How the mutated gene damages motor neurons is not understood. 
In particular, it is not known if the damaged gene directly affects 
motor neuron function or if other cells are involved. Recent studies 
have found that even healthy motor neurons begin to show char-
acteristics of ALS when cultured with non-neuronal cells carrying 
the mutation.
The new studies, both published in the May Nature Neuroscience, 
suggest that the culprit is the star-shaped cells called astrocytes, which 
play many supportive roles in the brain. Working with motor neurons 
taken directly from mouse embryos, as well as neurons derived from 
mouse embryonic stem cells, researchers led by Serge Przedborski 
at Columbia University found in the first study that motor neurons 
carrying the human SOD mutation showed some abnormalities, but 
not neurodegeneration.9
However, astrocytes with the mutation triggered motor neuron 
death, following the same degenerative pathway as occurs in ALS. In 
addition, the team found that the astrocytes cause damage by releas-
ing a substance that is selectively toxic to motor neurons, in contrast 
to non-harmful substances released by other types of support cells, 
such as glia.
In the second study, Kevin Eggan and colleagues at Harvard 
University and Perugia University used embryonic stem cells from 
mice to create a model to study the same question.10 The researchers 
took stem cells of mice bred to have either the normal human SOD 
gene or the mutated version, then allowed them to differentiate 
into motor neurons in large numbers. Cells with the mutation went 
through the characteristic steps of the disease, leading to the death of 
motor neurons, which suggests that the stem-cell approach is an effec-
tive, long-term research model of ALS. In addition, both the normal 
and the mutated motor neurons showed signs of neurodegeneration 
when cultured with SOD-mutant support cells.
Both findings open up new routes to treatment by showing that 
ALS may result from factors, such as astrocytes, that are not intrinsic 
to the motor neuron but that affect it. They also show how stem cells 
can provide a powerful new tool for studying the process by which 
a disease unfolds—in the case of the latter study, the work even 
provides a cell-based method for screening potential new drugs.
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Research in 2007 plowed new ground in understanding and treating neurodegenerative diseases, including Alzheimer’s. A growing body of evidence is also leading to new insights into 
how the brain uses memories of the past to plan for the future.
No treatment has yet been proved to modify the course of 
Alzheimer’s disease, but researchers are drawing close on a number of 
fronts that, in combination, may advance treatment and maybe even 
prevention of Alzheimer’s disease. A protein called beta-amyloid is 
one focus, but research continues on other targets as well.
Beta-amyloid and Alzheimer’s
Several of the research advances concern beta-amyloid protein 
plaques and fibrils, which build up in the brains of patients with 
Alzheimer’s disease. Plaques form in spaces between brain cells, and 
fibrils (tangles) develop within brain cells, but research suggests that 
neurons are damaged and brain functions are impaired before such 
structures appear.
Results of diverse studies using synthetic beta-amyloid peptides, 
cell culture models, transgenic mice (genetically engineered to contain 
human DNA), and the human brain all point in one direction: 
progressive accumulation of beta-amyloid is toxic to cells long before 
visible plaques and fibrils form. The subunits, or building blocks, of 
beta-amyloid protein were the subject of much research in 2007.
A team led by Lennart Mucke at the University of California, 
San Francisco, studied transgenic mice that have large amounts of 
beta-amyloid subunits in their brains; the animals exhibit many of the 
symptoms of Alzheimer’s, including cognitive deficits.1
The researchers found high levels of nonconvulsive seizure activity 
in the hippocampus and cortex, structures known to be important to 
memory. In those regions, beta-amyloid subunits cause an increased 
rate of firing in certain excitatory neuronal circuits. In response, 
inhibitory circuits remodel themselves. The effect is a reduction in the 
firing rate of the excitatory circuits.
The team concluded that the cognitive deficits associated with 
Alzheimer’s disease may result from the combination of excessive 
neuronal firing, caused by beta-amyloid subunits, followed by 
compensatory remodeling of inhibitory circuits. The remodeling may 
impair the function of the excitatory circuits.
Mucke suggests that treatments that block beta-amyloid-induced 
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over-excitement of neurons might prevent the activation of inhibitory 
pathways, their subsequent remodeling, and the cognitive impair-
ments that ensue.
Elsewhere, a Northwestern University team led by William Klein 
investigated how beta-amyloid-driven subunits called ADDLs affect 
synapse composition, structure, and abundance.2 These molecules 
build up in the brain and the cerebrospinal fluid. They attach to 
synapses, where they interfere with plasticity, the ability of the synapse 
to change. Eventually, the synapse degenerates, bringing on the 
memory loss of early Alzheimer’s disease.
Klein and his team investigated dendritic spines, which are 
outgrowths on the smaller, branching extensions of neurons. In most 
neurons, dendrites carry impulses toward the nerve cell body.
Using neurons cultured from the hippocampus, Klein and his 
colleagues found that ADDLs bind to dendritic spines in specific kinds 
of neurons and cause an increase in the number of certain memory-
related receptors. Continued exposure leads to abnormally long, thin 
dendritic spines and, eventually, to a reduction in the number of 
spines. As a result, synapses deteriorate. The anti-Alzheimer’s drug 
Namenda blocks both effects, the researchers found.
In a related study, a team led by Bernardo Sabatini at Harvard 
demonstrated that two- and three-molecule subunits (but not single-
molecule subunits) from beta-amyloid-derived proteins brought on 
progressive loss of synapses in hippocampal cells.3 The density of 
spines on dendrites and the number of active synapses in pyramidal 
neurons declined after exposure to the small, soluble molecules.
ADDLs, toxic proteins 
that build up in the brain 
and cerebrospinal fluid in 
Alzheimer’s disease, attack the 
memory-building synapses of a 
brain cell. Researchers in 2007 
studied the effect of ADDLs. 
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Beta-amyloid-specific antibodies reversed the loss of spines, as did 
a substance that prevented the buildup of the small molecules into 
larger units. Sabatini concluded that small, soluble subunits of beta-
amyloid trigger the loss of synapses.
The exact molecular structure of these soluble, diffusible subunits 
that merge into visible plaques and fibrils is still being probed. 
Nevertheless, therapies aimed at preventing the production of the 
subunits are being developed and tested. The goal of such treatments 
is to slow or even halt the deterioration of neuronal circuits before 
Alzheimer’s symptoms appear.4
Genetic Variants
Beta-amyloid is made from amyloid precursor protein (APP) in 
several parts of the cell. One important step in beta-amyloid manu-
facturing occurs during the re-entry and recycling of APP as it moves 
from the cell surface through a specific pathway inside the cell. A large 
international team of researchers led by Peter St. George-Hyslop of 
the University of Toronto reasoned that inherited differences in that 
pathway might affect both the processing of APP and the risk of 
developing Alzheimer’s.
They reported in Nature Genetics that inherited differences in a 
gene called SORL1 are associated with late-onset Alzheimer’s disease.5 
The variants occur in at least two different clusters of noncoding DNA 
within the SORL1 gene. These clusters may regulate how SORL1 is 
expressed in brain tissues.
The team found that SORL1 directs APP into recycling pathways. 
When there is a shortage of SORL1, APP is sorted into compartments 
where beta-amyloid proteins form. The researchers concluded that 
inherited or acquired changes in SORL1 expression or function are 
one cause of Alzheimer’s disease.
Other Targets for Treatment
Beta-amyloid proteins are not the only targets for potential 
Alzheimer’s treatment. Another is a protein called tau.
Tau is abundant in normal neurons. It interacts with the protein 
tubulin to promote and stabilize microtubules, the hollow, cylinder-
shaped structures in a cell that support it and move materials 
through it.
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However, certain abnormal forms of tau can trigger the assembly 
of the tangles and filaments found in the neurons of Alzheimer’s 
patients. Researchers are attempting to learn whether treatments 
aimed at tau can block beta-amyloid-induced cognitive impairments.
A team led by Eric Roberson at the Gladstone Institute of 
Neurological Disease in San Francisco used transgenic mice to probe 
this question. The mice were engineered to express high levels of 
amyloid precursor protein. They were tested in a water maze for 
learning and memory. Roberson found that reducing tau levels in 
tissues preserved the animals’ ability to learn the maze, even though 
their beta-amyloid levels were high.
In addition, Roberson found that tau reduction protected both 
transgenic and nontransgenic mice against something called excito-
toxicity, which occurs when a type of amino acid in the brain becomes 
toxic to neurons. The study, published in Science, concluded that 
reducing tau can block both beta-amyloid and excitotoxic dysfunc-
tion in neurons.6 Thus, tau reduction may represent an effective 
strategy for treating Alzheimer’s disease and related conditions.
Another potential therapy is a peptide called NAP that has been 
shown to protect against beta-amyloid-induced neuron death. NAP 
appears to block the buildup of beta-amyloid into plaques and fibrils. 
It also binds to tubulin, thereby preventing the microtubule disrup-
tion associated with Alzheimer’s.
Paul Aisen and his research team at Georgetown University studied 
transgenic mice that show both hallmarks of Alzheimer’s: accumula-
tion of beta-amyloid and the modified forms of tau associated with 
microtubule dysfunction. The team gave the mice daily doses of NAP 
for three months, beginning at age nine months—before disease 
symptoms appeared.
They reported in the Journal of Molecular Neuroscience that the treat-
ment significantly lowered beta-amyloid levels in the animals’ brains.7 
NAP also reduced levels of abnormal tau. The researchers conclude 
that NAP might offer promise as a treatment for Alzheimer’s.
Meanwhile, researchers at the Massachusetts Institute of Technology 
studied mice in which they could control the loss of neurons in certain 
Another potential therapy is a peptide called NAP that has been 
shown to protect against beta-amyloid-induced neuron death.
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places and for short periods. Some of the mice were placed in an 
“enriched environment”—their cages contained running wheels, toys, 
tunnels, and climbing devices. In this enriched environment, the mice 
regained their learning behavior and reestablished access to long-term 
memories, even after brain atrophy and neuronal loss had occurred.
The team studied the genetic material present in the brain tissue 
of the mice. The scientists were especially interested in the histone 
tails of chromatin, the complex of DNA and proteins that makes up 
chromosomes. Chromatin strands contain histones, a type of protein 
around which DNA coils. Histones are what primarily make up the 
tails, or ends, of chromatin strands.
The researchers found that chemical changes in these histone 
tails occurred when the environment was enriched. When those 
same changes were induced by a drug that inhibits the activity of 
a related enzyme called HDAC, dendrites sprouted, the number of 
synapses increased, and learning behavior and access to long-term 
memory improved. The researchers concluded in their May 10 Nature 
article that drugs that inhibit the enzyme might help in treatment of 
Alzheimer’s and other forms of dementia.8
Other researchers are probing how HDAC enzyme inhibitors 
work. Do they alter the expression of many genes and affect memory 
processes in a general way? Or is their action targeted? One study 
found two specific effects. One relates to a protein called CREB, 
which is formed inside the neuron and is known to be important to 
memory formation. Inhibitors also affect the expression of several 
individual genes during memory consolidation.9
Predicting Alzheimer’s
A team led by David Holtzman at Washington University in St. 
Louis reported in the Archives of Neurology in March 2007 that ratios 
of certain types of beta-amyloid and tau can help identify whether 
someone with normal cognition has amyloid deposits in the brain, 
increasing the chances that dementia will develop.
The researchers analyzed the cerebrospinal fluid and blood of 
139 volunteers, ages 60 to 91, who had been diagnosed as cognitively 
normal or having very mild or mild dementia.10 The team found that 
individuals with very mild or mild Alzheimer’s have less of a certain 
type of beta-amyloid and more tau in their cerebrospinal fluid 
than healthy controls. Levels of this beta-amyloid type predicted 
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whether amyloid was present in the brains of people with and 
without dementia.
Remembering and Imagining
Also in 2007, a growing number of researchers explored the 
relationship between remembering the past and imagining the future. 
People who have suffered damage to the hippocampus have difficulty 
remembering past events and imagining future scenarios. People with 
schizophrenia also recall fewer specific past events and imagine fewer 
specific future events than do normal subjects, reported Arnaud 
D’Argembeau of the University of Liège in Belgium. The research is 
reported in the Journal of Abnormal Psychology.11
Similar findings emerged in a Harvard study reported in 
Psychological Science. A team of researchers studied episodic memory 
in healthy older adults and college students. Episodic memory is 
important because it allows the recall of personal incidents that 
uniquely define an individual’s life. It lets people project themselves 
both backward and forward in subjective time.
When the team asked the volunteers to generate past and future 
events, the older adults came up with fewer episode-specific details 
relating to past events than younger adults did. The same effect 
occurred for future events: imagined happenings contained less 
episodic information.12 One result of the loss of episodic memory is 
that older adults sometimes have trouble integrating information and 
forming relations between items.
Neuroimaging studies show evidence of shared brain regions for 
remembering the past and imagining the future. In one study, 21 
volunteers raging in age from 18 to 32 underwent magnetic resonance 
imaging while remembering past events and imagining future events 
in response to event cues.13 The scans revealed a striking overlap in 
the activity associated with past and future events: the processes of 
remembering the past and imagining the future are associated with 
a core brain system that includes the prefrontal and medial temporal 
One result of the loss of episodic memory is that older adults 
sometimes have trouble integrating information and forming 
relations between items.
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lobe regions, as well as posterior regions (including the precuneus and 
the retrosplenial cortex) that are consistently observed as components 
of the brain’s memory retrieval network.
Findings such as these have led to the concept of the “prospective 
brain,” the idea that the brain uses stored information to imagine, 
simulate, and predict possible future events. The concept offers 
a new way of thinking about and studying memory, according to 
Harvard psychologists Daniel Schacter, Donna Rose Addis, and 
Randy Buckner.14 It suggests that both remembering and imagining 
use shared networks to retrieve stored information.
Imagining, however, requires the recombination of details in new 
ways, for which additional brain regions must be recruited. This 
overlap may explain why recall fails as a perfect recording of the 
past and functions instead as a constructive process. The ability to 
reorganize and reshape information stored in memory may be crucial 
to planning for the future, Schacter, Addis, and Buckner say.
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The DAnA AllIAnce  
for BrAIn InITIATIves
Mission statement,  
Goals, and Membership
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Dana Alliance Vision Statement - 2001
Imagine a world…
in which Alzheimer’s, Parkinson’s, Lou Gehrig’s (ALS) diseases, and •	
retinitis pigmentosa and other causes of blindness are commonly 
detected in their early stages, and are swiftly treated by medica-
tions that stop deterioration before significant damage occurs.
in which spinal cord injury doesn’t mean a lifetime of paralysis •	
because the nervous system can be programmed to re-wire neural 
circuits and re-establish muscle movement.
in which drug addiction and alcoholism no longer hold people’s •	
lives hostage because easily available treatments can interrupt the 
changes in neural pathways that cause withdrawal from, and drive 
the craving for, addictive substances.
in which the genetic pathways and environmental triggers that •	
predispose people to mental illness are understood so that accurate 
diagnostic tests and targeted therapies—including medications, 
counseling, and preventive interventions—are widely available and 
fully employed.
in which new knowledge about brain development is used to •	
enhance the benefits of the crucial early learning years and combat 
diseases associated with aging.
in which people’s daily lives are not compromised by attacks of •	
depression or anxiety because better medications are being devel-
oped to treat these conditions.
A lthough such a vision may seem unrealistic and utopian, we are at an extraordinarily exciting time in the history of neuroscience. The advances in research during the past decade have taken us further than we had 
imagined. We have expanded our understanding of the basic mechanisms of how 
the brain works, and are at a point where we can harness the healing potential 
of that knowledge.
We have already begun to devise strategies, new technologies, and treat-
ments to combat a range of neurological diseases and disorders. By setting 
therapeutic goals, and applying what we know, we will develop effective 
treatments—and, in some instances, cures.
For all that has been learned in neuroscience recently, we are learning how 
much we do not know. That creates the urgency to continue basic research 
that looks at the broader questions of how living things work. This will help to 
formulate the complex questions that lead to scientific discovery.
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The coordinated work of thousands of basic and clinical scientists in multiple 
disciplines, ranging from molecular structure and drug design to genomics, 
brain imaging, cognitive science, and clinical investigation, has given us a pool 
of information that we can now use to build into therapeutic applications for 
all neurological diseases and disorders. As scientists, we will continue to move 
forward not just as individuals, exploring our particular areas of interest, but 
also in concert with colleagues in all areas of science, mining opportunities to 
collaborate across disciplines.
Public confidence in science is essential if we are to be successful in our 
mission. To this end we recognize that dialogue between researchers and the 
public will be essential in considering the ethical and social consequences of 
advances in brain research.
The Dana Alliance for Brain Initiatives and the European Dana Alliance for 
the Brain represent a community of neuroscientists willing to commit to ambi-
tious goals, as seen in 1992 in Cold Spring Harbor, New York, where an American 
research agenda was set forth and again in 1997 when the newly formed 
European group followed suit with its own goals and objectives. Both groups 
now are moving to build upon gains made so far. We are setting new goals to 
guide what can be achieved in the near term, and project even further into the 
future. By allowing ourselves to imagine what benefit to humanity this new 
era in neuroscience is likely to bring, we can speed progress toward achieving 
our goals.
The Goals
Combat the devastating impact of Alzheimer’s disease.
In Alzheimer’s disease, a small piece of the protein amyloid accumulates and 
is toxic to nerve cells. The mechanism of this accumulation has been worked out 
biochemically and in genetic studies in animals. Using these animal models, new 
therapeutic drugs and a potentially powerful vaccine are being developed to 
prevent the accumulation of this toxic material or enhance its removal. These 
new therapies, which will be tried in humans in the near future, offer realistic 
hope that this disease process can be effectively treated.
Discover how best to treat Parkinson’s disease.
Drugs that act on dopamine pathways in the brain have had significant 
success in treating the motor abnormalities of Parkinson’s disease. Unfortunately, 
this therapeutic benefit wears off for many patients after 5–10 years. New drugs 
are being developed to prolong the action of dopamine-based treatments and to 
slow the selective loss of nerve cells that causes this disease. For those in whom 
drug therapies fail, surgical approaches, such as deep brain stimulation, are 
likely to be of benefit. Newer forms of brain imaging have made it possible to 
determine if these treatments are rescuing nerve cells and restoring their circuits 
back toward normal.
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Decrease the incidence of stroke and 
improve post-stroke therapies.
Heart disease and stroke can be strikingly reduced when people stop smoking, 
keep their cholesterol levels low, maintain normal weight by diet and exercise, 
and when diabetes is detected and treated. For those with strokes, rapid evalu-
ation and treatment can lead to dramatic improvement and less disability. New 
treatments will be developed to further reduce the acute impact of stroke on 
normal brain cells. New rehabilitation techniques, based on understanding how 
the brain adjusts itself following injury, will result in further improvement.
Develop more successful treatments for mood 
disorders, such as depression, schizophrenia, obsessive 
compulsive disorder, and bipolar disorder.
Although the genes for these diseases have eluded researchers over the past 
decade, the sequencing of the human genome will reveal several of the genes 
for these conditions. New imaging techniques, along with new knowledge about 
the actions of these genes in the brain, will make it possible to see how certain 
brain circuits go awry in these disorders of mood and thought. This will provide 
the basis for better diagnosis of patients, more effective use of today’s medica-
tions, and the development of entirely new agents for treatment.
Uncover genetic and neurobiological causes 
of epilepsy and advance its treatment.
Understanding the genetic roots of epilepsy and the neural mechanisms that 
cause seizures will provide opportunities for preventive diagnosis and targeted 
therapies. Advances in electronic and surgical therapies promise to provide valu-
able treatment options.
Discover new and effective ways to prevent 
and treat multiple sclerosis.
For the first time, we have drugs that can modify the course of this disease. 
New drugs, aimed at altering the body’s immune responses, will continue to 
decrease the number and severity of attacks of multiple sclerosis. New approach-
es will be taken to stop the longer-term progression caused by the breakdown 
of nerve fibers.
Develop better treatments for brain tumors.
Many types of brain tumors, especially those that are malignant or have 
spread from cancer outside the brain, are difficult to treat. Imaging techniques, 
focused-radiation treatments, different forms of delivery of drugs to the tumor, 
and the identification of genetic markers that will assist diagnosis, should 
provide the basis for development of innovative therapies.
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Improve recovery from traumatic brain 
and spinal cord injuries.
Treatments are being evaluated that decrease the amount of injured tissue 
immediately after an injury. Other agents are aimed at promoting the rewiring 
of nerve fibers. Techniques that encourage cellular regeneration in the brain to 
replace dead and damaged neurons will advance from animal models to human 
clinical trials. Electronic prostheses are being developed that use microchip tech-
nology to control neural circuits and return movement to paralyzed limbs.
Create new approaches for pain management.
Pain, as a medical condition, need no longer be woefully undertreated. 
Research into the causation of pain and the neural mechanisms that drive it will 
give neuroscientists the tools they need to develop more effective and more 
highly targeted therapies for pain relief.
Treat addiction at its origins in the brain.
Researchers have identified the neural circuits involved in every known drug 
of abuse, and have cloned major receptors for these drugs. Advances in brain 
imaging, by identifying the neurobiological mechanisms that turn a normal 
brain into an addicted brain, will enable us to develop therapies that can either 
reverse or compensate for these changes.
Understand the brain mechanisms underlying the 
response to stress, anxiety, and depression.
Good mental health is a prerequisite for a good quality of life. Stress, anxiety, 
and depression not only damage peoples’ lives; they can also have a devastat-
ing impact on society. As we come to understand the body’s response to stress 
and the brain circuits implicated in anxiety and depression, we will be able to 
develop more effective ways to prevent them, and better treatments to lessen 
their impact.
The Strategy
Take advantage of the findings of genomic research.
The complete sequence of all the genes that comprise the human genome 
will soon be available. This means that we will be able, within the next 10 to 
15 years, to determine which genes are active in each region of the brain under 
different functional states, and at every stage in life—from early embryonic life, 
through infancy, adolescence, and throughout adulthood. It will be possible to 
identify which genes are altered so that their protein products are either missing 
or functioning abnormally in a variety of neurological and psychiatric disorders. 
Already this approach has enabled scientists to establish the genetic basis of 
such disorders as Huntington’s disease, the spinocerebellar ataxias, muscular 
dystrophy, and fragile-X mental retardation.
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The whole process of gene discovery and its use in clinical diagnosis prom-
ises to transform neurology and psychiatry and represents one of the greatest 
challenges to neuroscience. Fortunately the availability of microarrays or “gene 
chips” should greatly accelerate this endeavor and provide a powerful new tool 
both for diagnosis and for the design of new therapies.
Apply what we know about how the brain develops.
The brain passes through specific stages of development from conception until 
death, and through different stages and areas of vulnerability and growth that 
can be either enhanced or impaired. To improve treatment for developmental 
disorders such as autism, attention deficit disorder, and learning disabilities, 
neuroscience will build a more detailed picture of brain development. Because 
the brain also has unique problems associated with other stages of development, 
such as adolescence and aging, understanding how the brain changes during 
these periods will enable us to develop innovative treatments.
Harness the immense potential of the plasticity of the brain.
By harnessing the power of neuroplasticity—the ability of the brain to 
remodel and adjust itself—neuroscientists will advance treatments for degen-
erative neurological diseases and offer ways to improve brain function in both 
healthy and disease states. In the next ten years, cell replacement therapies 
and the promotion of new brain cell formation will lead to new treatments for 
stroke, spinal cord injury, and Parkinson’s disease.
Expand our understanding of what makes us uniquely human.
How does the brain work? Neuroscientists are at the point where they can 
ask—and begin to answer—the big questions. What are the mechanisms and 
underlying neural circuits that allow us to form memories, pay attention, feel 
and express our emotions, make decisions, use language, and foster creativity? 
Efforts to develop a “unified field theory” of the brain will offer great opportu-
nities to maximize human potential.
The Tools
Cell replacement
Adult nerve cells cannot replicate themselves to replace cells lost due to 
disease or injury. Technologies that use the ability of neural stem cells (the 
progenitors of neurons) to differentiate into new neurons have the potential to 
revolutionize the treatment of neurological disorders. Transplants of neural stem 
cells, currently being done on animal models, will rapidly reach human clinical 
trial status. How to control the development of these cells, direct them to the 
right place, and cause them to make the appropriate connections are all active 
areas of research.
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Neural repair mechanisms
By using the nervous system’s own repair mechanisms—in some cases, 
regenerating new neurons and in others restoring the wiring—the brain has the 
potential to “fix” itself. The ability to enhance these processes provides hope for 
recovery after spinal cord injury or head injuries.
Technologies that may arrest or prevent neurodegeneration
Many conditions, such as Parkinson’s disease, Alzheimer’s disease, Huntington’s 
disease, and ALS are the result of degeneration in specific populations of nerve 
cells in particular regions of the brain. Our present treatments, which modify the 
symptoms in a disease like Parkinson’s disease, do not alter this progressive loss 
of nerve cells. Techniques that draw on our knowledge of the mechanisms of cell 
death are likely to offer methods to prevent neurodegeneration and, in this way, 
stop the progression of these diseases.
Technologies that modify genetic expression in the brain
It is possible to either enhance or block the action of specific genes in the 
brains of experimental animals. Mutated human genes that cause neurological 
diseases, such as Huntington’s and ALS, are being used in animal models to assist 
in the development of new therapies to prevent neurodegeneration. Such tech-
niques have also provided valuable information about normal processes, such as 
development of the brain, learning, and the formation of new memories. These 
technologies provide an approach to the study of normal and abnormal brain 
processes more powerful than there has ever been available before and, in time, 
may be used clinically in the treatment of many brain disorders.
Advanced imaging techniques
There have been remarkable advances in imaging both the structure and the 
function of the brain. By developing techniques that image brain functions as 
quickly and accurately as the brain does, we can achieve “real-time” imaging of 
brain functions. These technologies will allow neuroscientists to see exactly which 
parts of the brain are involved as we think, learn, and experience emotions.
Electronic aids to replace non-functional brain pathways
In time it may be possible to bypass injured pathways in the brain. Using 
multi-electrode array implants and micro-computer devices—which monitor 
activity in the brain and translate it into signals to the spinal cord, motor nerves, 
or directly to muscles—we expect to be able to offer the injured hope for func-
tional recovery.
Novel methods of drug discovery
Advances in structural biology, genomics, and computational chemistry are 
enabling scientists to generate unprecedented numbers of new drugs, many of 
which promise to be of considerable value in clinical practice. The development 
of new, rapid screening procedures, using “gene chips” and other high through-
put technologies, will reduce the time between the discovery of a new drug and 
its clinical evaluation, in some cases, from years to just a few months.
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Our Commitment, Bench to Bedside
Today, neuroscience research benefits from an unprecedented breadth 
of opportunity. We have expanded our understanding of brain function, 
disease onset, and disease progression. A sophisticated arsenal of tools and 
techniques now enables us to apply our knowledge and accelerate progress in 
brain research.
As scientists, we are committed to continue making progress “at the bench.” 
To attack major brain disorders, such as Alzheimer’s, stroke, or Parkinson’s, will 
require continued basic research from which clinicians can move toward develop-
ment of new treatments and therapies. We have a responsibility to continue such 
research and to enlist its support by the public.
We also have the obligation to explain those areas of scientific research that 
soon may have direct application to human beings. To progress beyond labora-
tory research, we need to take the next clinical steps in partnership with the 
public—translating science into real and genuine benefits “at the bedside.”
As our tools and techniques become more sophisticated, they may be 
considered threatening in their perceived potential for misuse. It is important to 
recognize the understandable fears that brain research may allow scientists to 
alter the most important aspects of our brains and behavior, changing the very 
things that make us uniquely human. Public confidence in the integrity of scien-
tists, in the safety of clinical trials—the cornerstone of applied research—and in 
the assurance of patient confidentiality, must be continually maintained.
Putting research into a real-life context is always a challenge. People not 
only want to know how and why research is done, they also want to know why 
it matters to them. Allaying the public’s concerns that the findings of brain 
science could be used in ways that might be harmful or ethically questionable 
is particularly important. Meeting both of these challenges is essential if those 
affected by neurological or psychiatric disorders are to reap fully the benefits of 
brain research.
Our mission as neuroscientists has to go beyond brain research. We accept 
our responsibility to explain in plain language where our science, and its new 
tools and techniques, are likely to take us. We, the members of the Dana Alliance 
and the European Dana Alliance willingly embrace this mission as we embark on 
a new decade of hope, hard work, and partnership with the public.
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Brain and Mind
CeReBRum 2008: emerging Ideas in Brain Science
Foreword by Carl Zimmer
The second annual anthology drawn from Cerebrum’s highly regarded Web edition, Cerebrum 
2008 brings together an international roster of scientists and other scholars to interpret the latest 
discoveries about the human brain and confront their implications.
Paper •225 pp • ISBN-13: 978-1-932594-33-1 • $14.95
CereBrum 2007: emerging Ideas in Brain Science
Paper • 243 pp • ISBN-13: 978-1-932594-24-9 • $14.95
Visit Cerebrum online at www.dana.org/news/cerebrum.
Your BraIN oN CuBS: Inside the Heads of Players and Fans
Dan Gordon, Editor
our brains light up with the rush that accompanies a come-from-behind win—and the crush 
of a disappointing loss. Brain research also offers new insight into how players become experts. 
Neuroscientists and science writers explore these topics and more in this intriguing look at talent and 
triumph on the field and our devotion in the stands.
6 illustrations.
Cloth • 150 pp • ISBN-13: 978-1-932594-28-7 • $19.95
The NeuroSCIeNCe of faIr PlaY:  
Why We (usually) Follow the Golden Rule
Donald W. Pfaff, Ph.D.
a distinguished neuroscientist presents a rock-solid hypothesis of why humans across time and 
geography have such similar notions of good and bad, right and wrong.
10 illustrations.
Cloth • 234 pp • ISBN-13: 978-1-932594-27-0 • $20.95
BeST of The BraIN from SCIeNTIfIC amerICaN:  
mind, matter, and Tomorrow’s Brain
Floyd E. Bloom, M.D., Editor
Top neuroscientist floyd e. Bloom has selected the most fascinating brain-related articles from 
Scientific american and Scientific american mind since 1999 in this collection.
30 illustrations.
Cloth • 300 pp • ISBN-13: 978-1-932594-22-5 • $25.00
mINd WarS: Brain research and National defense
Jonathan D. Moreno, Ph.D.
A leading ethicist examines national security agencies’ work on defense applications of brain science, 
and the ethical issues to consider.
Cloth • 210 pp • ISBN-10: 1-932594-16-7 • $23.95
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The daNa GuIde To BraIN healTh:  
a Practical family reference from medical experts (with Cd-rom)
Floyd E. Bloom, M.D., M. Flint Beal, M.D., and David J. Kupfer, M.D., Editors
Foreword by William Safire
a complete, authoritative, family-friendly guide to the brain’s development, health, and disorders.
16 full-color pages and more than 200 black-and-white drawings.
Paper (with Cd-rom) • 733 pp • ISBN-10: 1-932594-10-8 • $25.00
The CreaTING BraIN: The Neuroscience of Genius
Nancy C. Andreasen, M.D., Ph.D.
a noted psychiatrist and best-selling author explores how the brain achieves creative breakthroughs, 
including questions such as how creative people are different and the difference between genius and 
intelligence.
33 illustrations/photos.
Cloth • 197 pp • ISBN-10: 1-932594-07-8 • $23.95
The eThICal BraIN
Michael S. Gazzaniga, Ph.D.
explores how the lessons of neuroscience help resolve today’s ethical dilemmas, ranging from when 
life begins to free will and criminal responsibility.
Cloth • 201 pp • ISBN-10: 1-932594-01-9 • $25.00
a Good STarT IN lIfe:  
understanding Your Child’s Brain and Behavior from Birth to Age 6
Norbert Herschkowitz, M.D., and Elinore Chapman Herschkowitz
The authors show how brain development shapes a child’s personality and behavior, discussing 
appropriate rule-setting, the child’s moral sense, temperament, language, playing, aggression, 
impulse control, and empathy.
13 illustrations.
Cloth • 283 pp • ISBN-10: 0-309-07639-0 • $22.95 
Paper (updated with new material) • 312 pp • ISBN-10: 0-9723830-5-0 • $13.95
BaCk from The BrINk:  
how Crises Spur doctors to New discoveries about the Brain
Edward J. Sylvester
In two academic medical centers, Columbia’s New York Presbyterian and Johns hopkins medical 
Institutions, a new breed of doctor, the neurointensivist, saves patients with life-threatening 
brain injuries.
16 illustrations/photos.
Cloth • 296 pp • ISBN-10: 0-9723830-4-2 • $25.00
The Bard oN The BraIN:  
understanding the mind Through the Art of Shakespeare and the Science of Brain Imaging
Paul M. Matthews, M.D., and Jeffrey McQuain, Ph.D. • Foreword by Diane Ackerman
explores the beauty and mystery of the human mind and the workings of the brain, following the 
path the Bard pointed out in 35 of the most famous speeches from his plays.
100 illustrations.
Cloth • 248 pp • ISBN-10: 0-9723830-2-6 • $35.00
STrIkING BaCk aT STroke: a doctor-Patient Journal
Cleo Hutton and Louis R. Caplan, M.D.
A personal account, with medical guidance from a leading neurologist, for anyone enduring the 
changes that a stroke can bring to a life, a family, and a sense of self.
15 illustrations.
Cloth • 240 pp • ISBN-10: 0-9723830-1-8 • $27.00
uNderSTaNdING dePreSSIoN:  
What We know and What You Can do about It
J. Raymond DePaulo, Jr., M.D., and Leslie Alan Horvitz
Foreword by Kay Redfield Jamison, Ph.D.
What depression is, who gets it and why, what happens in the brain, troubles that come with the 
illness, and the treatments that work.
Cloth • 304 pp • ISBN-10: 0-471-39552-8 • $24.95 
Paper • 296 pp • ISBN-10: 0-471-43030-7 • $14.95
keeP Your BraIN YouNG:  
The Complete Guide to Physical and emotional health and longevity
Guy M. McKhann, M.D., and Marilyn Albert, Ph.D.
every aspect of aging and the brain: changes in memory, nutrition, mood, sleep, and sex, as well as 
the later problems in alcohol use, vision, hearing, movement, and balance.
Cloth • 304 pp • ISBN-10: 0-471-40792-5 • $24.95 
Paper • 304 pp • ISBN-10: 0-471-43028-5 • $15.95
The eNd of STreSS aS We kNoW IT
Bruce S. McEwen, Ph.D., with Elizabeth Norton Lasley • Foreword by Robert Sapolsky
How brain and body work under stress and how it is possible to avoid its debilitating effects.
Cloth • 239 pp • ISBN-10: 0-309-07640-4 • $27.95 
Paper • 262 pp • ISBN-10: 0-309-09121-7 • $19.95
IN SearCh of The loST Cord:  
Solving the mystery of Spinal Cord Regeneration
Luba Vikhanski
The story of the scientists and science involved in the international scientific race to find ways to 
repair the damaged spinal cord and restore movement.
21 photos; 12 illustrations.
Cloth • 269 pp • ISBN-10: 0-309-07437-1 • $27.95
The SeCreT lIfe of The BraIN
Richard Restak, M.D. • Foreword by David Grubin
Companion book to the PBS series of the same name, exploring recent discoveries about the brain 
from infancy through old age.
Cloth • 201 pp • ISBN-10: 0-309-07435-5 • $35.00
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The loNGevITY STraTeGY:  
how to live to 100 using the Brain-Body Connection
David Mahoney and Richard Restak, M.D. • Foreword by William Safire
Advice on the brain and aging well.
Cloth • 250 pp • ISBN-10: 0-471-24867-3 • $22.95 
Paper • 272 pp • ISBN-10: 0-471-32794-8 • $14.95
STaTeS of mINd: New discoveries about how our Brains make us Who We are
Roberta Conlan, Editor
adapted from the dana/Smithsonian associates lecture series by eight of the country’s top brain 
scientists, including the 2000 Nobel laureate in medicine, eric kandel.
Cloth • 214 pp • ISBN-10: 0-471-29963-4 • $24.95 
Paper • 224 pp • ISBN-10: 0-471-39973-6 • $18.95
The Dana Foundation Series on Neuroethics
defINING rIGhT aNd WroNG IN BraIN SCIeNCe:  
essential readings in Neuroethics
Walter Glannon, Ph.D., Editor
The fifth volume in The dana foundation Series on Neuroethics, this collection marks the five-
year anniversary of the first meeting in the field of neuroethics, providing readers with the seminal 
writings on the past, present, and future ethical issues facing neuroscience and society.
Cloth • 350 pp • ISBN-10: 978-1-932594-25-6 • $15.95
hard SCIeNCe, hard ChoICeS:  
Facts, ethics, and Policies Guiding Brain Science Today
Sandra J. Ackerman, Editor
Top scholars and scientists discuss new and complex medical and social ethics brought about by 
advances in neuroscience. Based on an invitational meeting co-sponsored by the library of Congress, 
the National Institutes of health, the Columbia university Center for Bioethics, and the dana 
Foundation.
Paper • 152 pp • ISBN-10: 1-932594-02-7 • $12.95
NeuroSCIeNCe aNd The laW: Brain, mind, and the Scales of Justice
Brent Garland, Editor. With commissioned papers by Michael S. Gazzaniga, Ph.D., and 
Megan S. Steven; Laurence R. Tancredi, M.D., J.D.; Henry T. Greely, J.D.; and Stephen J. 
Morse, J.D., Ph.D.
How discoveries in neuroscience influence criminal and civil justice, based on an invitational meeting 
of 26 top neuroscientists, legal scholars, attorneys, and state and federal judges convened by the 
dana foundation and the american association for the advancement of Science.
Paper • 226 pp • ISBN-10: 1-032594-04-3 • $8.95
BeYoNd TheraPY: Biotechnology and the Pursuit of Happiness
A Report of the President’s Council on Bioethics
Special Foreword by Leon R. Kass, M.D., Chairman
Introduction by William Safire
Can biotechnology satisfy human desires for better children, superior performance, ageless bodies, 
and happy souls? This report says these possibilities present us with profound ethical challenges and 
choices. Includes dissenting commentary by scientist members of the Council.
Paper • 376 pp • ISBN-10: 1-932594-05-1 • $10.95
NeuroeThICS: mapping the Field. Conference Proceedings
Steven J. Marcus, Editor
Proceedings of the landmark 2002 conference organized by Stanford university and the university 
of California, San francisco, and sponsored by the dana foundation, at which more than 150 
neuroscientists, bioethicists, psychiatrists and psychologists, philosophers, and professors of law and 
public policy debated the ethical implications of neuroscience research findings.
50 illustrations.
Paper • 367 pp • ISBN-10: 0-9723830-0-X • $10.95
Immunology
reSISTaNCe: The Human Struggle Against Infection
Norbert Gualde, M.D., translated by Steven Rendall
Traces the histories of epidemics and the emergence or re-emergence of diseases, illustrating how 
new global strategies and research of the body’s own weapons of immunity can work together to 
fight tomorrow’s inevitable infectious outbreaks.
Cloth • 219 pp • ISBN-10: 1-932594-00-0 • $25.00
faTal SequeNCe: The Killer Within
Kevin J. Tracey, M.D.
An easily understood account of the spiral of sepsis, a sometimes fatal crisis that most often affects 
patients fighting off nonfatal illnesses or injury. Tracey puts the scientific and medical story of sepsis 
in the context of his battle to save a burned baby, a sensitive telling of cutting-edge science.
Cloth • 231 pp • ISBN-10: 1-932594-06-X • $23.95
Paper • 231 pp • ISBN-10: 1-932594-09-4 • $12.95
Arts education
a Well-TemPered mINd: using music to help Children listen and learn
Peter Perret and Janet Fox • Foreword by Maya Angelou
Five musicians enter elementary school classrooms, helping children learn about music and 
contributing to both higher enthusiasm and improved academic performance. This charming story 
gives us a taste of things to come in one of the newest areas of brain research: the effect of music on 
the brain.
12 illustrations.
Cloth • 225 pp • ISBN-10: 1-932594-03-5 • $22.95
Paper • 225 pp • ISBN-10: 1-932594-08-6 • $12.00
Dana Press also offers several free periodicals dealing with arts 
education, immunology, and brain science. For more informa-
tion, please visit www.dana.org.
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